Chronic Pain: Epidemiology, Pathophysiology, and Clinical Management

Abstract

Chronic pain represents a pervasive global health crisis and a leading cause of disability, yet its management remains challenged by the intricate heterogeneity of its underlying mechanisms. Transcending traditional symptom-based paradigms, chronic pain is now recognized as a distinct disease entity driven by multidimensional maladaptive plasticity. In this review, we synthesize the current landscape of chronic pain, bridging macrolevel epidemiological burdens with microlevel pathophysiological insights. We dissect the complex biological networks driving pain chronification, ranging from peripheral sensitization and ion channel dysfunction to central synaptic reorganization, spinal disinhibition, and maladaptive neuro–immune crosstalk involving glial activation and autoantibody-mediated mechanisms. Notably, we highlight emerging frontiers, including sexual dimorphism in immune signaling, metabolic reprogramming, and epigenetic memory. Furthermore, we critically evaluate the evolution of clinical management strategies, integrating pharmacological innovations, advanced neuromodulation, and digital therapeutics. Finally, we address the persistent translational chasm between basic discovery and clinical efficacy, advocating for a paradigm shift from “one-size-fits-all” approaches toward mechanism-based precision medicine—underpinned by robust biomarkers and deep phenotyping—to revolutionize therapeutic outcomes.

Keywords

chronic pain / global burden / maladaptive neural plasticity / multidisciplinary approaches / neuro–immune interactions / precision medicine

References

[1] C. M. Lam, M. Sanderson, D. T. Vu, et al., “Musculoskeletal and Neuropathic Pain in COVID-19,” Diagnostics 14 (2024): 332.

[2] A. Barke, B. Korwisi, R. Jakob, N. Konstanjsek, W. Rief, and R. Treede, “Classification of Chronic Pain for the International Classification of Diseases (ICD-11): Results of the 2017 International World Health Organization Field Testing,” Pain 163 (2022): e310–e318.

[3] B. H. Smith, E. A. Fors, B. Korwisi, et al., “The IASP Classification of Chronic Pain for ICD-11: Applicability in Primary Care,” Pain 160 (2019): 83–87.

[4] M. Nicholas, J. W. S. Vlaeyen, W. Rief, et al., “The IASP Classification of Chronic Pain for ICD-11: Chronic Primary Pain,” Pain 160 (2019): 28–37.

[5] A. Barke, B. Korwisi, and W. Rief, “Chronic Pain in the ICD-11: New Diagnoses That Clinical Psychologists Should Know about,” Clinical Psychology in Europe 4 (2022): e9933.

[6] Q. Wang, Y. Zhang, H. Zhang, and Z. Li, “Spinal Cord Stimulation: An Emerging Strategy for Chronic Pain Relief After Spinal Cord Injury,” Neural Regeneration Research (2025): 10–4103.

[7] J. Boselie and M. L. Peters, “Shifting the Perspective: How Positive Thinking Can Help Diminish the Negative Effects of Pain,” Scandinavian Journal of Pain 23 (2023): 452–463.

[8] O. Gemin, P. Serna, J. Zamith, et al., “Unique Properties of Dually Innervated Dendritic Spines in Pyramidal Neurons of the Somatosensory Cortex Uncovered by 3D Correlative Light and Electron Microscopy,” Plos Biology 19 (2021): e3001375.

[9] B. Stevens, K. R. Monk, and M. R. Freeman, “The Biology of Glia,” CSH Perspectives in Biology 17 (2025): a041809.

[10] J. S. Bhatti, S. Kaur, J. Mishra, et al., “Targeting Dynamin-related Protein-1 as a Potential Therapeutic Approach for Mitochondrial Dysfunction in Alzheimer's Disease,” Biochimica et Biophysica Acta Molecular Basis of Disease 1869 (2023): 166798.

[11] Y. Vijayanathan and I. A. W. Ho, “The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies,” International Journal of Molecular Sciences 26 (2025): 669.

[12] Z. Li, X. Li, J. Liu, et al., “Molecular Mechanisms of Chronic Pain and Therapeutic Interventions,” Medcomm 6 (2025): e70325.

[13] A. Alcántara Montero, “Update on the Treatment of Neuropathic Pain From the Neuropathic Pain Special Interest Group of International Association for the Study of Pain,” Revista Espanola de Anestesiologia y Reanimacion 72 (2025): 501856.

[14] L. Almeida De Oliveira, A. R. Gross, L. Carlesso, et al., “Graded Activity for Chronic Low Back Pain,” Cochrane Database of Systematic Reviews 2 (2025): CD015507.

[15] C. G. Ryan, E. L. Karran, S. B. Wallwork, et al., “We Are All in This Together-Whole of Community Pain Science Education Campaigns to Promote Better Management of Persistent Pain,” The Journal of Pain 25 (2024): 902–917.

[16] A. Shetty, G. Delanerolle, H. Cavalini, et al., “A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain,” Scientific Reports-UK 14 (2024): 1621.

[17] C. Rometsch, A. Martin, F. Junne, and F. Cosci, “Chronic Pain in European Adult Populations: A Systematic Review of Prevalence and Associated Clinical Features,” Pain 166 (2025): 719–731.

[18] J. Dahlhamer, J. Lucas, C. Zelaya, et al., “Prevalence of Chronic Pain and High-Impact Chronic Pain among Adults—United States, 2016,” MMWR Morbidity and Mortality Weekly Report 67 (2018): 1001–1006.

[19] S. N. El-Tallawy, R. Nalamasu, G. I. Salem, J. A. K. LeQuang, J. V. Pergolizzi, and P. J. Christo, “Management of Musculoskeletal Pain: An Update With Emphasis on Chronic Musculoskeletal Pain,” Pain and Therapy 10 (2021): 181–209.

[20] S. M. Rikard, A. E. Strahan, K. M. Schmit, and G. P. J. Guy, “Chronic Pain among Adults—United States, 2019–2021,” MMWR Morbidity and Mortality Weekly Report 72 (2023): 379–385.

[21] A. Zajacova, H. Grol-Prokopczyk, and R. L. Nahin, “Pain Among US Adults Before, During, and After the COVID-19 Pandemic: A Study Using the 2019 to 2023 National Health Interview Survey,” Pain 167, no. 1 (2025): 142–149.

[22] A. Daryabor and A. Akbarzadeh Baghban, “Comparison of a 30-year Trend of Incidence, Prevalence, and DALY due to Low Back Pain in Iran With Low- and High-SDI Countries; Based on GBD Study 2019 Data,” ARCH Academic Emergency Medicine 12 (2024): e39.

[23] Z. Zimmer, K. Fraser, H. Grol-Prokopczyk, and A. Zajacova, “A Global Study of Pain Prevalence Across 52 Countries: Examining the Role of Country-level Contextual Factors,” Pain 163 (2022): 1740–1750.

[24] A. Wu, L. March, X. Zheng, et al., “Global Low Back Pain Prevalence and Years Lived With Disability From 1990 to 2017: Estimates From the Global Burden of Disease Study 2017,” Annals of Translational Medicine 8 (2020): 299.

[25] L. R. The, “The Global Epidemic of Low Back Pain,” The Lancet Rheumatology 5 (2023): e305.

[26] G. M. Shetty, S. Jain, H. Thakur, and K. Khanna, “Prevalence of Low Back Pain in India: A Systematic Review and Meta-analysis,” Work (Reading, Mass) (Reading, Mass) 73 (2022): 429–452.

[27] I. M. B. de Souza, T. F. Sakaguchi, S. L. K. Yuan, et al., “Prevalence of Low Back Pain in the Elderly Population: A Systematic Review,” Clinics (Sao Paulo, Brazil) 74 (2019): e789.

[28] H. Long, Q. Liu, H. Yin, et al., “Prevalence Trends of Site-Specific Osteoarthritis from 1990 to 2019: Findings from the Global Burden of Disease Study 2019,” Arthritis & Rheumatology (Hoboken, NJ) 74 (2022): 1172–1183.

[29] GBD 2021 Osteoarthritis Collaborators. Global, Regional, and National Burden of Osteoarthritis, 1990–2020 and Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatology 2023; 5: e508–e522.

[30] D. Prieto-Alhambra, A. Judge, M. K. Javaid, C. Cooper, A. Diez-Perez, and N. K. Arden, “Incidence and Risk Factors for Clinically Diagnosed Knee, Hip and Hand Osteoarthritis: Influences of Age, Gender and Osteoarthritis Affecting Other Joints,” Annals of the Rheumatic Diseases 73 (2014): 1659–1664.

[31] F. Heidari, M. Afshari, and M. Moosazadeh, “Prevalence of Fibromyalgia in General Population and Patients, a Systematic Review and Meta-analysis,” Rheumatology International 37 (2017): 1527–1539.

[32] S. Y. Kim, A. J. Busch, T. J. Overend, et al., “Flexibility Exercise Training for Adults With Fibromyalgia,” Cochrane Database of Systematic Reviews 9 (2019): CD013419.

[33] O. van Hecke, S. K. Austin, R. A. Khan, B. H. Smith, and N. Torrance, “Neuropathic Pain in the General Population: A Systematic Review of Epidemiological Studies,” Pain 155 (2014): 654–662.

[34] G. Baskozos, H. L. Hébert, M. M. Pascal, et al., “Epidemiology of Neuropathic Pain: An Analysis of Prevalence and Associated Factors in UK Biobank,” PAIN Reports 8 (2023): e1066.

[35] R. Rugnath, C. Orzechowicz, C. Newell, V. Carullo, and A. Rugnath, “A Literature Review: The Mechanisms and Treatment of Neuropathic Pain-A Brief Discussion,” Biomedicines 12 (2024): 204.

[36] L. Al-Hassany, J. Haas, M. Piccininni, T. Kurth, A. Maassen Van Den Brink, and J. L. Rohmann, “Giving Researchers a Headache—Sex and Gender Differences in Migraine,” Frontiers in Neurology 11 (2020): 549038.

[37] W. Chen, F. Hsiao, and S. Wang, “Brain Excitability in Tension-Type Headache: A Separate Entity From Migraine?,” Current Pain and Headache Reports 24 (2021): 82.

[38] R. Ge, J. Chang, and Y. Cao, “Headache Disorders and Relevant Sex and Socioeconomic Patterns in Adolescents and Young Adults Across 204 Countries and territories: An Updated Global Analysis,” The Journal of Headache and Pain 24 (2023): 110.

[39] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England) 2018; 392: 1789–1858.

[40] R. A. H. Snijders, L. Brom, M. Theunissen, and M. H. J. van den Beuken-van Everdingen, “Update on Prevalence of Pain in Patients With Cancer 2022: A Systematic Literature Review and Meta-Analysis,” Cancers 15 (2023): 591.

[41] M. H. J. van den Beuken-van Everdingen, L. M. J. Hochstenbach, E. A. J. Joosten, V. C. G. Tjan-Heijnen, and D. J. A. Janssen, “Update on Prevalence of Pain in Patients with Cancer: Systematic Review and Meta-Analysis,” Journal of Pain and Symptom Management 51 (2016): 1070–1090.

[42] C. Jiang, H. Wang, Q. Wang, Y. Luo, R. Sidlow, and X. Han, “Prevalence of Chronic Pain and High-Impact Chronic Pain in Cancer Survivors in the United States,” JAMA Oncology 5 (2019): 1224–1226.

[43] Y. Luo, Z. Liu, L. Yang, et al., “Association of Body Pain and Chronic Disease: Evidence From a 7-year Population-based Study in China,” Regional Anesthesia & Pain Medicine 46 (2021): 745–751.

[44] QuickStats: Percentage* of Adults Aged ≥20 Years Who Had Chronic Pain,(†) by Veteran Status and Age Group—National Health Interview Survey, United States, 2019(§). MMWR Morbidity and Mortality Weekly Report 2020; 69: 1797.

[45] A. Tinnirello, S. Mazzoleni, and C. Santi, “Chronic Pain in the Elderly: Mechanisms and Distinctive Features,” Biomolecules 11 (2021): 1256.

[46] M. A. Khan, A. Rehman, and B. Nusrat, “Correlation of Fibromyalgia With Inflammatory Bowel Disease,” Journal of the College of Physicians and Surgeons–Pakistan: JCPSP 32 (2022): 689.

[47] A. Oliveira, D. Teixeira, F. D. S. Menezes, A. P. Marques, Y. Duarte, and R. A. Casarotto, “Socioeconomic and Sex Inequalities in Chronic Pain: A Population-based Cross-sectional Study,” PLoS ONE 18 (2023): e0285975.

[48] Á. Denche-Zamorano, D. Salas-Gómez, S. Barrios-Fernandez, P. Tomás-Carus, J. C. Adsuar, and J. A. Parraca, “Relationship between Frequency of Physical Activity, Functional Mobility, and Self-Perceived Health in People With Different Levels of Pain: A Cross-Sectional Study,” Journal of Functional Morphology and Kinesiology 9 (2024): 198.

[49] M. F. Rossi, A. Tumminello, M. Marconi, et al., “Sex and Gender Differences in Migraines: A Narrative Review,” Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 43 (2022): 5729–5734.

[50] G. Pujolar-Díaz, Q. Miró Catalina, A. Fuster-Casanovas, L. Sola Reguant, and J. Vidal-Alaball, “A Sex- and Gender-Based Approach to Chronic Conditions in Central Catalonia (Spain): A Descriptive Cross-Sectional Study,” International Journal of Environmental Research and Public Health 21 (2024): 152.

[51] G. Puto, I. Repka, and A. Gniadek, “Gender Differences in the Quantitative and Qualitative Assessment of Chronic Pain Among Older People,” Frontiers in Public Health 12 (2024): 1344381.

[52] A. M. McIntosh, L. S. Hall, Y. Zeng, et al., “Genetic and Environmental Risk for Chronic Pain and the Contribution of Risk Variants for Major Depressive Disorder: A Family-Based Mixed-Model Analysis,” Plos Medicine 13 (2016): e1002090.

[53] L. J. Hocking, S. Generation, A. D. Morris, A. F. Dominiczak, D. J. Porteous, and B. H. Smith, “Heritability of Chronic Pain in 2195 Extended Families,” European Journal of Pain (London, England) 16 (2012): 1053–1063.

[54] A. V. Bortsov, M. Parisien, S. Khoury, et al., “Brain-specific Genes Contribute to Chronic but Not to Acute Back Pain,” PAIN Reports 7 (2022): e1018.

[55] K. Leźnicka, M. Pawlak, M. Sawczuk, A. Gasiorowska, and A. Leońska-Duniec, “SCN9A rs6746030 Polymorphism and Pain Perception in Combat Athletes and Non-Athletes,” Genes-Basel 14 (2023): 733.

[56] P. Hsu, C. Cheng, H. Chao, et al., “OPRM1 A118G Polymorphism Modulating Motor Pathway for Pain Adaptability in Women With Primary Dysmenorrhea,” Frontiers in Neuroscience-Switz 17 (2023): 1179851.

[57] J. Steinle, W. A. Hossain, O. J. Veatch, S. P. Strom, and M. G. Butler, “Next-generation Sequencing and Analysis of Consecutive Patients Referred for Connective Tissue Disorders,” American Journal of Medical Genetics Part A 188 (2022): 3016–3023.

[58] N. Valvi, J. A. Tamargo, D. Braithwaite, R. B. Fillingim, and S. D. Karanth, “Household Income Is Associated With Chronic Pain and High-Impact Chronic Pain Among Cancer Survivors: A Cross-Sectional Study Using NHIS Data,” Cancers 16 (2024): 2847.

[59] D. G. Blanchflower and A. Bryson, “Chronic Pain: Evidence From the National Child Development Study,” PLoS ONE 17 (2022): e0275095.

[60] M. Sauter, J. Barthelme, C. Müller, and F. Liebers, “Manual Handling of Heavy Loads and Low Back Pain Among Different Occupational Groups: Results of the 2018 BIBB/BAuA Employment Survey,” BMC Musculoskeletal Disorders 22 (2021): 956.

[61] M. Bovenzi and M. Schust, “A Prospective Cohort Study of Low-back Outcomes and Alternative Measures of Cumulative External and Internal Vibration Load on the Lumbar Spine of Professional Drivers,” Scandinavian Journal of Work, Environment & Health 47 (2021): 277–286.

[62] Y. Lee, X. Hong, and S. S. Man, “Prevalence and Associated Factors of Work-Related Musculoskeletal Disorders Symptoms Among Construction Workers: A Cross-Sectional Study in South China,” International Journal of Environmental Research and Public Health 20 (2023): 4653.

[63] A. Farioli, S. Mattioli, A. Quaglieri, S. Curti, F. S. Violante, and D. Coggon, “Musculoskeletal Pain in Europe: The Role of Personal, Occupational, and Social Risk Factors,” Scandinavian Journal of Work, Environment & Health 40 (2014): 36–46.

[64] B. Rezaei, E. Mousavi, B. Heshmati, and S. Asadi, “Low Back Pain and Its Related Risk Factors in Health Care Providers at Hospitals: A Systematic Review,” Annals of Medicine and Surgery 70 (2021): 102903.

[65] S. Koda, A. Hisashige, T. Ogawa, et al., “An Epidemiological Study on Low Back Pain and Occupational Risk Factors Among Clinical Nurses,” Sangyo Igaku Japanese Journal of Industrial Health 33 (1991): 410–422.

[66] D. Yokoyama, S. Tamura, K. Fujisaki, et al., “Influence of Caregiver Understanding of Their Capability to Perform Activities of Daily Living, Disease Comprehension, and Attitudes on Occupational Low Back Pain: A Cross-sectional Study,” Journal of Physical Therapy Science 36 (2024): 577–582.

[67] A. Abdullahi, K. Aliyu, A. B. Hassan, et al., “Prevalence of Chronic Non-specific Low Back Pain Among Caregivers of Stroke Survivors in Kano, Nigeria and Factors Associated With It: A Cross-sectional Study,” Frontiers in Neurology 13 (2022): 900308.

[68] R. Shumnalieva, G. Kotov, P. Ermencheva, and S. Monov, “Pathogenic Mechanisms and Therapeutic Approaches in Obesity-Related Knee Osteoarthritis,” Biomedicines 12 (2023): 9.

[69] L. Luo, M. Li, W. Huang, et al., “Obesity Aggravates the Role of C-reactive Protein on Knee Pain: A Cross-sectional Analysis With NHANES Data,” Immunity, Inflammation and Disease 12 (2024): e1371.

[70] X. Chen, H. Tang, J. Lin, and R. Zeng, “Causal Relationships of Obesity on Musculoskeletal Chronic Pain: A Two-sample Mendelian Randomization Study,” Frontiers in Endocrinology 13 (2022): 971997.

[71] W. Encinosa, D. Bernard, and R. B. Valdez, “Corrigendum to “the Association Between Smoking, chronic pain, and prescription opioid use: 2013–2021” [J Pain 26 (2025) 104707],” The Journal of Pain 26 (2025): 104734.

[72] M. Lee, J. Snow, C. Quon, et al., “I Smoke to Cope With Pain: Patients' perspectives on the Link Between Cigarette Smoking and Pain,” Wiener Klinische Wochenschrift 133 (2021): 1012–1019.

[73] L. A. Bastian, M. Driscoll, E. DeRycke, et al., “Pain and Smoking Study (PASS): A Comparative Effectiveness Trial of Smoking Cessation Counseling for Veterans With Chronic Pain,” Contemporary Clinical Trials Communications 23 (2021): 100839.

[74] M. Lindell and A. Grimby-Ekman, “Stress, non-restorative Sleep, and Physical Inactivity as Risk Factors for Chronic Pain in Young Adults: A Cohort Study,” PLoS ONE 17 (2022): e0262601.

[75] J. Fanning, A. K. Brooks, J. T. Robison, et al., “Associations Between Patterns of Physical Activity, Pain Intensity, and Interference Among Older Adults With Chronic Pain: A Secondary Analysis of Two Randomized Controlled Trials,” Frontiers in Aging 4 (2023): 1216942.

[76] J. B. Lesnak, G. Berardi, and K. A. Sluka, “Influence of Routine Exercise on the Peripheral Immune System to Prevent and Alleviate Pain,” Neurobiology of Pain (Cambridge, Mass) 13 (2023): 100126.

[77] R. V. Aaron, S. G. Ravyts, N. D. Carnahan, et al., “Prevalence of Depression and Anxiety among Adults with Chronic Pain: A Systematic Review and Meta-Analysis,” JAMA Network Open 8 (2025): e250268.

[78] J. Li, Y. Cui, Q. Jia, A. Ouyang, and Y. Hua, “Pain Intensity and Pain Catastrophizing among Patients With Chronic Pain: The Mediating Effect of Self-Efficacy,” Journal of Pain Research 18 (2025): 1361–1373.

[79] J. A. Beebe, C. Kronman, F. Mahmud, et al., “Gait Variability and Relationships with Fear, Avoidance, and Pain in Adolescents with Chronic Pain,” Physical Therapy 101 (2021): pzab012.

[80] M. Karimov-Zwienenberg, W. Symphor, W. Peraud, and G. Décamps, “Childhood Trauma, PTSD/CPTSD and Chronic Pain: A Systematic Review,” PLoS ONE 19 (2024): e0309332.

[81] A. Stubhaug, J. L. Hansen, S. Hallberg, A. Gustavsson, A. E. Eggen, and C. S. Nielsen, “The Costs of Chronic Pain-Long-term Estimates,” European Journal of Pain (London, England) 28 (2024): 960–977.

[82] Z. Campwala, G. Davis, O. Khazen, et al., “The Impact of Multidisciplinary Conferences on Healthcare Utilization in Chronic Pain Patients,” Frontiers in Pain Research (Lausanne, Switzerland) 2 (2021): 775210.

[83] K. G. Dobson, C. Mustard, N. Carnide, A. Furlan, and P. M. Smith, “Impact of Persistent Pain Symptoms on Work Absence, Health Status and Employment 18 Months Following Disabling Work-related Injury or Illness,” Occupational and Environmental Medicine 79 (2022): 697–705.

[84] C. S. Nielsen, “Assessing the Societal Cost of Chronic Pain,” Scandinavian Journal of Pain 22 (2022): 684–685.

[85] S. Mayer, J. Spickschen, K. V. Stein, R. Crevenna, T. E. Dorner, and J. Simon, “The Societal Costs of Chronic Pain and Its Determinants: The Case of Austria,” PLoS ONE 14 (2019): e0213889.

[86] A. Anselmo, M. Pagano, I. Cappadona, et al., “A Systematic Review on the Neuropsychological Assessment of Patients With LBP: The Impact of Chronic Pain on Quality of Life,” Journal of Clinical Medicine 13 (2024): 6149.

[87] F. F. Pandelani, S. L. N. Nyalunga, and T. Pandelani, “Chronic Pain: The Prevalence of Chronic Pain in Patients Attending Soshanguve Community Health Centre,” Canadian Journal of Pain 8 (2023): 2284152.

[88] J. S. De La Rosa, B. R. Brady, M. M. Ibrahim, et al., “Co-occurrence of Chronic Pain and Anxiety/Depression Symptoms in U.S. adults: Prevalence, Functional Impacts, and Opportunities,” Pain 165 (2024): 666–673.

[89] B. Wallace, C. Varcoe, C. Holmes, et al., “Towards Health Equity for People Experiencing Chronic Pain and Social Marginalization,” International Journal for Equity in Health 20 (2021): 53.

[90] D. Koesling and C. Bozzaro, “Chronic Pain Patients' need for Recognition and Their Current Struggle,” Medicine, Health Care, and Philosophy 24 (2021): 563–572.

[91] B. Cao, Q. Xu, Y. Shi, et al., “Pathology of Pain and Its Implications for Therapeutic Interventions,” Signal Transduction and Targeted Therapy 9 (2024): 155.

[92] T. J. Price and P. R. Ray, “Recent Advances Toward Understanding the Mysteries of the Acute to Chronic Pain Transition,” Current Opinion in Physiology 11 (2019): 42–50.

[93] D. B. Reichling and J. D. Levine, “Critical Role of Nociceptor Plasticity in Chronic Pain,” Trends in Neuroscience (Tins) 32 (2009): 611–618.

[94] B. K. Taylor and G. Corder, “Endogenous Analgesia, Dependence, and Latent Pain Sensitization,” Current Topics in Behavioral Neurosciences 20 (2014): 283–325.

[95] R. Y. North, Y. Li, P. Ray, et al., “Electrophysiological and Transcriptomic Correlates of Neuropathic Pain in human Dorsal Root Ganglion Neurons,” Brain: A Journal of Neurology 142 (2019): 1215–1226.

[96] S. Rosen, B. Ham, and J. S. Mogil, “Sex Differences in Neuroimmunity and Pain,” Journal of Neuroscience Research 95 (2017): 500–508.

[97] D. L. Bennett, A. J. Clark, J. Huang, S. G. Waxman, and S. D. Dib-Hajj, “The Role of Voltage-Gated Sodium Channels in Pain Signaling,” Physiological Reviews 99 (2019): 1079–1151.

[98] O. Moriarty, Y. Tu, A. S. Sengar, M. W. Salter, S. Beggs, and S. M. Walker, “Priming of Adult Incision Response by Early-Life Injury: Neonatal Microglial Inhibition Has Persistent but Sexually Dimorphic Effects in Adult Rats,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 39 (2019): 3081–3093.

[99] F. R. Nieto, S. M. Vuckovic, and M. S. Prostran, “Editorial: Mechanisms and New Targets for the Treatment of Chronic Pain,” Frontiers in Pharmacology 11 (2020): 600037.

[100] Z. Huang, X. Li, Y. Wang, et al., “Circadian Rhythms and Pain: A Narrative Review on Clock Genes and Circadian-Based Interventions,” Journal of Pain Research 18 (2025): 4687–4698.

[101] A. Goebel, E. Krock, C. Gentry, et al., “Passive Transfer of Fibromyalgia Symptoms From Patients to Mice,” The Journal of Clinical Investigation 131 (2021): e144201.

[102] O. Seifert and C. Baerwald, “Interaction of Pain and Chronic Inflammation,” Zeitschrift Fur Rheumatologie 80 (2021): 205–213.

[103] R. Malhotra, “Understanding Migraine: Potential Role of Neurogenic Inflammation,” Annals of Indian Academy of Neurology 19 (2016): 175–182.

[104] A. McGinnis and R. Ji, “The Similar and Distinct Roles of Satellite Glial Cells and Spinal Astrocytes in Neuropathic Pain,” Cells-Basel 12 (2023): 965.

[105] N. P. Nelson-Maney, L. Bálint, A. L. Beeson, et al., “Meningeal Lymphatic CGRP Signaling Governs Pain via Cerebrospinal Fluid Efflux and Neuroinflammation in Migraine Models,” The Journal of Clinical Investigation 134 (2024): e175616.

[106] Z. Chen, C. Zhang, X. Song, et al., “BzATP Activates Satellite Glial Cells and Increases the Excitability of Dorsal Root Ganglia Neurons in Vivo,” Cells-Basel 11 (2022): 2280.

[107] S. J. Chhaya, D. Quiros-Molina, A. D. Tamashiro-Orrego, J. D. Houlé, and M. R. Detloff, “Exercise-Induced Changes to the Macrophage Response in the Dorsal Root Ganglia Prevent Neuropathic Pain After Spinal Cord Injury,” Journal of Neurotrauma 36 (2019): 877–890.

[108] A. Dormer, M. Narayanan, J. Schentag, et al., “A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials,” Journal of Pain Research 16 (2023): 1487–1498.

[109] S. Yamakita, D. Fujita, K. Sudo, et al., “Activation of Neurons and Satellite Glial Cells in the DRG Produces Morphine-induced Hyperalgesia,” Molecular Pain 19 (2023): 17448069231181973.

[110] H. Li, Y. Huang, Y. Zhou, et al., “C-X-C Motif Chemokine 10 Contributes to the Development of Neuropathic Pain by Increasing the Permeability of the Blood-Spinal Cord Barrier,” Frontiers in Immunology 11 (2020): 477.

[111] A. Fernández-Carvajal, G. Fernández-Ballester, and A. Ferrer-Montiel, “TRPV1 in Chronic Pruritus and Pain: Soft Modulation as a Therapeutic Strategy,” Frontiers in Molecular Neuroscience 15 (2022): 930964.

[112] R. Ji, T. A. Samad, S. Jin, R. Schmoll, and C. J. Woolf, “p38 MAPK Activation by NGF in Primary Sensory Neurons After Inflammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia,” Neuron 36 (2002): 57–68.

[113] D. Souza Monteiro De Araujo, R. Nassini, P. Geppetti, and F. De Logu, “TRPA1 as a Therapeutic Target for Nociceptive Pain,” Expert Opinion on Therapeutic Targets 24 (2020): 997–1008.

[114] C. De Caro, C. Cristiano, C. Avagliano, et al., “Characterization of New TRPM8 Modulators in Pain Perception,” International Journal of Molecular Sciences 20 (2019): 5544.

[115] P. Arsenault, D. Chiche, W. Brown, et al., “NEO6860, modality-selective TRPV1 Antagonist: A Randomized, Controlled, Proof-of-concept Trial in Patients With Osteoarthritis Knee Pain,” PAIN Reports 3 (2018): e696.

[116] Z. S. Chen, “Hierarchical Predictive Coding in Distributed Pain Circuits,” Frontiers in Neural Circuits 17 (2023): 1073537.

[117] G. Rankin, A. M. Chirila, A. J. Emanuel, et al., “Nerve Injury Disrupts Temporal Processing in the Spinal Cord Dorsal Horn Through Alterations in PV(+) Interneurons,” Cell Reports 43 (2024): 113718.

[118] D. S. Matasic, N. Holland, M. Gautam, et al., “Paradoxical Potentiation of Acid-Sensing Ion Channel 3 (ASIC3) by Amiloride via Multiple Mechanisms and Sites within the Channel,” Frontiers in Physiology 12 (2021): 750696.

[119] T. Khataei and C. J. Benson, “ASIC3 plays a Protective Role in Delayed-onset Muscle Soreness (DOMS) Through Muscle Acid Sensation During Exercise,” Frontiers in Pain Research (Lausanne, Switzerland) 4 (2023): 1215197.

[120] M. Marchi, I. D'Amato, M. Andelic, et al., “Congenital Insensitivity to Pain: A Novel Mutation Affecting a U12-type Intron Causes Multiple Aberrant Splicing of SCN9A,” Pain 163 (2022): e882–e887.

[121] R. R. Atmaramani, B. J. Black, J. B. de la Peña, Z. T. Campbell, and J. J. Pancrazio, “Conserved Expression of Nav1.7 and Nav1.8 Contribute to the Spontaneous and Thermally Evoked Excitability in IL-6 and NGF-Sensitized Adult Dorsal Root Ganglion Neurons in Vitro,” Bioengineering-Basel 7 (2020): 44.

[122] A. McDonnell, S. Collins, Z. Ali, et al., “Efficacy of the Nav1.7 Blocker PF-05089771 in a Randomised, Placebo-controlled, Double-blind Clinical Study in Subjects With Painful Diabetic Peripheral Neuropathy,” Pain 159 (2018): 1465–1476.

[123] P. Shinu, M. A. Morsy, A. B. Nair, et al., “Novel Therapies for the Treatment of Neuropathic Pain: Potential and Pitfalls,” Journal of Clinical Medicine 11 (2022): 3002.

[124] P. T. Nguyen and V. Yarov-Yarovoy, “Towards Structure-Guided Development of Pain Therapeutics Targeting Voltage-Gated Sodium Channels,” Frontiers in Pharmacology 13 (2022): 842032.

[125] C. Tang, K. Gomez, Y. Chen, et al., “C2230, a Preferential Use- and state-dependent CaV2.2 Channel Blocker, Mitigates Pain Behaviors Across Multiple Pain Models,” The Journal of Clinical Investigation 135 (2024): e177429.

[126] J. Peng, N. Gu, L. Zhou, et al., “Microglia and Monocytes Synergistically Promote the Transition From Acute to Chronic Pain After Nerve Injury,” Nature Communications 7 (2016): 12029.

[127] Y. Zheng, S. Shao, Y. Zhang, et al., “HCN2 Channels in the Ventral Hippocampal CA1 Regulate Nociceptive Hypersensitivity in Mice,” International Journal of Molecular Sciences 24 (2023): 13823.

[128] F. Denk, S. B. McMahon, and I. Tracey, “Pain Vulnerability: A Neurobiological Perspective,” Nature Neuroscience 17 (2014): 192–200.

[129] A. Abd-Elsayed, M. Jackson, S. L. Gu, K. Fiala, and J. Gu, “Neuropathic Pain and Kv7 Voltage-gated Potassium Channels: The Potential Role of Kv7 Activators in the Treatment of Neuropathic Pain,” Molecular Pain 15 (2019): 1744806919864256.

[130] R. J. Porter, A. Partiot, R. Sachdeo, V. Nohria, W. M. Alves, and G. Study, “Randomized, Multicenter, Dose-ranging Trial of Retigabine for Partial-onset Seizures,” Neurology 68 (2007): 1197–1204.

[131] M. J. Brodie, H. Lerche, A. Gil-Nagel, et al., “Efficacy and Safety of Adjunctive Ezogabine (retigabine) in Refractory Partial Epilepsy,” Neurology 75 (2010): 1817–1824.

[132] R. E. Sorge, J. C. S. Mapplebeck, S. Rosen, et al., “Different Immune Cells Mediate Mechanical Pain Hypersensitivity in Male and Female Mice,” Nature Neuroscience 18 (2015): 1081–1083.

[133] P. Cheng, G. E. M. Yuan-He, D. Ye, J. Chen, and J. Wang, “Targeting the Main Sources of Reactive Oxygen Species Production: Possible Therapeutic Implications in Chronic Pain,” Current Neuropharmacology 22 (2024): 1960–1985.

[134] P. Silva Santos Ribeiro, H. Willemen, S. Versteeg, C. Martin Gil, and N. Eijkelkamp, “NLRP3 inflammasome Activation in Sensory Neurons Promotes Chronic Inflammatory and Osteoarthritis Pain,” Immunotherapy Advances 3 (2023): ltad022.

[135] M. Sajic, A. E. Rumora, A. A. Kanhai, et al., “High Dietary Fat Consumption Impairs Axonal Mitochondrial Function in Vivo,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 41 (2021): 4321–4334.

[136] C. Khuankaew, N. Apaijai, P. Sawaddiruk, et al., “Effect of Coenzyme Q10 on Mitochondrial respiratory Proteins in Trigeminal Neuralgia,” Free Radical Research 52 (2018): 415–425.

[137] S. A. Eid, A. E. Rumora, B. Beirowski, et al., “New Perspectives in Diabetic Neuropathy,” Neuron 111 (2023): 2623–2641.

[138] F. Bouçanova, G. Pollmeier, K. Sandor, et al., “Disrupted Function of Lactate Transporter MCT1, but Not MCT4, in Schwann Cells Affects the Maintenance of Motor End-plate Innervation,” Glia 69 (2021): 124–136.

[139] R. Field, F. Pourkazemi, and K. Rooney, “Effects of a Low-Carbohydrate Ketogenic Diet on Reported Pain, Blood Biomarkers and Quality of Life in Patients With Chronic Pain: A Pilot Randomized Clinical Trial,” Pain Medicine (Malden, Mass) 23 (2022): 326–338.

[140] Y. Huang, S. Chen, H. Chen, J. Zhou, D. Jin, and H. Pan, “Theta-Burst Stimulation of Primary Afferents Drives Long-Term Potentiation in the Spinal Cord and Persistent Pain via α2δ-1-Bound NMDA Receptors,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 42 (2022): 513–527.

[141] J. Hu, X. Chen, J. Cheng, F. Kong, H. Xia, and J. Wu, “Mammalian Target of Rapamycin Signaling Pathway Is Involved in Synaptic Plasticity of the Spinal Dorsal Horn and Neuropathic Pain in Rats by Regulating Autophagy,” Neuroreport 32 (2021): 925–935.

[142] Y. Li, W. Shi, J. Dai, et al., “Upregulated TNF-α and Lactate Following ERK-SGK1 Activation in the Spinal Dorsal Horn Underlies Chronic Postsurgical Pain,” Chinese Journal of Physiology 66 (2023): 144–152.

[143] Y. Zang, D. Jiang, X. Zhuang, and S. Chen, “Changes in the central Nervous System in Diabetic Neuropathy,” Heliyon 9 (2023): e18368.

[144] M. Shi, J. Zhou, R. Hu, et al., “EA Participates in Pain Transition Through Regulating KCC2 Expression by BDNF-TrkB in the Spinal Cord Dorsal Horn of Male Rats,” Neurobiology of Pain (Cambridge, Mass) 13 (2023): 100115.

[145] M. Xue, Y. Sun, Y. Xia, Z. Huang, C. Huang, and G. Xing, “Electroacupuncture Modulates Spinal BDNF/TrκB Signaling Pathway and Ameliorates the Sensitization of Dorsal Horn WDR Neurons in Spared Nerve Injury Rats,” International Journal of Molecular Sciences 21 (2020): 6524.

[146] P. A. Smith, “Neuropathic Pain; What We Know and What We Should Do About It,” Frontiers in Pain Research (Lausanne, Switzerland) 4 (2023): 1220034.

[147] S. Dai, Y. Qi, J. Fu, et al., “Dexmedetomidine Attenuates Persistent Postsurgical Pain by Upregulating K(+)-Cl(-) Cotransporter-2 in the Spinal Dorsal Horn in Rats,” Journal of Pain Research 11 (2018): 993–1004.

[148] J. Ma, T. Zhang, X. Diao, et al., “BDNF Modulated KCC2 Ubiquitylation in Spinal Cord Dorsal Horn of Mice,” European Journal of Pharmacology 906 (2021): 174205.

[149] T. Ishibashi, Y. Yoshikawa, D. Sueto, et al., “Selective Involvement of a Subset of Spinal Dorsal Horn Neurons Operated by a Prodynorphin Promoter in Aβ Fiber-Mediated Neuropathic Allodynia-Like Behavioral Responses in Rats,” Frontiers in Molecular Neuroscience 15 (2022): 911122.

[150] M. A. Gradwell, K. A. Boyle, T. J. Browne, et al., “Diversity of Inhibitory and Excitatory Parvalbumin Interneuron Circuits in the Dorsal Horn,” Pain 163 (2022): e432–e452.

[151] T. Follansbee, H. Le Chang, M. Iodi Carstens, Y. Guan, E. Carstens, and X. Dong, “Optotagging and Characterization of GABAergic Rostral Ventromedial Medulla (RVM) Neurons,” Molecular Pain 20 (2024): 17448069241270295.

[152] L. Heijmans, M. R. Mons, and E. A. Joosten, “A Systematic Review on Descending Serotonergic Projections and Modulation of Spinal Nociception in Chronic Neuropathic Pain and After Spinal Cord Stimulation,” Molecular Pain 17 (2021): 17448069211043965.

[153] A. H. Cooper, N. S. Hedden, P. Prasoon, Y. Qi, and B. K. Taylor, “Postsurgical Latent Pain Sensitization Is Driven by Descending Serotonergic Facilitation and Masked by μ-Opioid Receptor Constitutive Activity in the Rostral Ventromedial Medulla,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 42 (2022): 5870–5881.

[154] S. T. Lubejko, G. Livrizzi, S. A. Buczynski, et al., “Inputs to the Locus Coeruleus From the Periaqueductal Gray and Rostroventral Medulla Shape Opioid-mediated Descending Pain Modulation,” Science Advances 10 (2024): eadj9581.

[155] F. Aby, L. Lorenzo, Z. Grivet, et al., “Switch of Serotonergic Descending Inhibition Into Facilitation by a Spinal Chloride Imbalance in Neuropathic Pain,” Science Advances 8 (2022): eabo0689.

[156] C. Robinson, S. Dalal, A. Chitneni, et al., “A Look at Commonly Utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Chronic Pain,” Health Psychology Research 10 (2022): 32309.

[157] A. Etkin, T. Egner, and R. Kalisch, “Emotional Processing in Anterior Cingulate and Medial Prefrontal Cortex,” Trends in Cognitive Sciences 15 (2011): 85–93.

[158] R. Kalisch, K. Wiech, H. D. Critchley, and R. J. Dolan, “Levels of Appraisal: A Medial Prefrontal Role in High-level Appraisal of Emotional Material,” Neuroimage 30 (2006): 1458–1466.

[159] D. J. Hohenschurz-Schmidt, G. Calcagnini, O. Dipasquale, et al., “Linking Pain Sensation to the Autonomic Nervous System: The Role of the Anterior Cingulate and Periaqueductal Gray Resting-State Networks,” Frontiers in Neuroscience-Switz 14 (2020): 147.

[160] J. Kim, M. L. Loggia, C. M. Cahalan, et al., “The Somatosensory Link in Fibromyalgia: Functional Connectivity of the Primary Somatosensory Cortex Is Altered by Sustained Pain and Is Associated With Clinical/Autonomic Dysfunction,” Arthritis & Rheumatology (Hoboken, NJ) 67 (2015): 1395–1405.

[161] R. Harrison, W. Gandhi, C. M. van Reekum, and T. V. Salomons, “Conditioned Pain Modulation Is Associated With Heightened Connectivity Between the Periaqueductal Grey and Cortical Regions,” PAIN Reports 7 (2022): e999.

[162] J. P. Sanabria-Mazo, A. Colomer-Carbonell, Ó. Fernández-Vázquez, et al., “A Systematic Review of Cognitive Behavioral Therapy-based Interventions for Comorbid Chronic Pain and Clinically Relevant Psychological Distress,” Frontiers in Psychology 14 (2023): 1200685.

[163] S. G. J. Boccard, J. J. Fitzgerald, E. A. C. Pereira, et al., “Targeting the Affective Component of Chronic Pain: A Case Series of Deep Brain Stimulation of the Anterior Cingulate Cortex,” Neurosurgery 74 (2014): 628–637.

[164] E. Makovac, A. Venezia, D. Hohenschurz-Schmidt, et al., “The Association Between Pain-induced Autonomic Reactivity and Descending Pain Control Is Mediated by the Periaqueductal Grey,” The Journal of Physiology 599 (2021): 5243–5260.

[165] S. K. Ng, D. M. Urquhart, P. B. Fitzgerald, et al., “Examining Resting-state Functional Connectivity in Key Hubs of the Default Mode Network in Chronic Low Back Pain,” Scandinavian Journal of Pain 21 (2021): 839–846.

[166] J. Kim, I. Mawla, J. Kong, et al., “Somatotopically Specific Primary Somatosensory Connectivity to Salience and Default Mode Networks Encodes Clinical Pain,” Pain 160 (2019): 1594–1605.

[167] C. C. Hays Weeks, A. N. Simmons, I. A. Strigo, S. Timtim, R. J. Ellis, and J. R. Keltner, “Distal Neuropathic Pain in HIV Is Associated With Functional Connectivity Patterns in Default Mode and Salience networks,” Frontiers in Pain Research (Lausanne, Switzerland) 3 (2022): 1004060.

[168] A. T. Henn, B. Larsen, L. Frahm, et al., “Structural Imaging Studies of Patients With Chronic Pain: An Anatomical Likelihood Estimate Meta-analysis,” Pain 164 (2023): e10–e24.

[169] S. F. Farrell, A. I. Campos, P. Kho, et al., “Genetic Basis to Structural Grey Matter Associations With Chronic Pain,” Brain: A Journal of Neurology 144 (2021): 3611–3622.

[170] N. Gao, H. Shi, S. Hu, et al., “Acupuncture Enhances Dorsal Raphe Functional Connectivity in Knee Osteoarthritis with Chronic Pain,” Frontiers in Neurology 12 (2022): 813723.

[171] Y. Song, M. Yao, H. Kemprecos, et al., “Predictive Coding Models for Pain Perception,” Journal of Computational Neuroscience 49 (2021): 107–127.

[172] A. Grahl, S. Onat, and C. Büchel, “The Periaqueductal Gray and Bayesian Integration in Placebo Analgesia,” Elife 7 (2018): e32930.

[173] J. Castejón, F. Chen, A. Yasoda-Mohan, C. Ó Sé, and S. Vanneste, “Chronic Pain—A Maladaptive Compensation to Unbalanced Hierarchical Predictive Processing,” Neuroimage 297 (2024): 120711.

[174] H. R. Schone, C. I. Baker, J. Katz, et al., “Making Sense of Phantom Limb Pain,” Journal of Neurology, Neurosurgery, and Psychiatry 93 (2022): 833–843.

[175] F. Benedetti, E. Carlino, and A. Pollo, “How Placebos Change the Patient's Brain,” Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 36 (2011): 339–354.

[176] M. Chen, X. Wu, L. Zhang, et al., “Neural Mechanisms Underlying Placebo and Nocebo Effects in Tonic Muscle Pain,” Neuroimage 300 (2024): 120877.

[177] J. Lee and J. Lee, “Discovering Individual Fingerprints in Resting-state Functional Connectivity Using Deep Neural Networks,” Human Brain Mapping 45 (2024): e26561.

[178] E. J. Corti, W. Marinovic, A. T. Nguyen, N. Gasson, and A. M. Loftus, “Motor Cortex Excitability in Chronic Low Back Pain,” Experimental Brain Research 240 (2022): 3249–3257.

[179] J. Liu, J. Huang, Z. Zhang, et al., “Translocator Protein 18 kDa (TSPO) as a Novel Therapeutic Target for Chronic Pain,” Neural Plasticity 2022 (2022): 8057854.

[180] M. Terumitsu, Y. Takado, K. Fukuda, E. Kato, and S. Tanaka, “Neurometabolite Levels and Relevance to Central Sensitization in Chronic Orofacial Pain Patients: A Magnetic Resonance Spectroscopy Study,” Journal of Pain Research 15 (2022): 1421–1432.

[181] Z. Zhang, J. S. Gewandter, and P. Geha, “Brain Imaging Biomarkers for Chronic Pain,” Frontiers in Neurology 12 (2022): 734821.

[182] S. Eldabe, I. Obara, C. Panwar, and D. Caraway, “Biomarkers for Chronic Pain: Significance and Summary of Recent Advances,” Pain Research & Management 2022 (2022): 1940906.

[183] K. Inoue, “Overview for the Study of P2 Receptors: From P2 Receptor History to Neuropathic Pain Studies,” Journal of Pharmacological Sciences 149 (2022): 73–80.

[184] D. Gilabert, A. Duveau, S. Carracedo, et al., “Microglial P2×4 Receptors Are Essential for Spinal Neurons Hyperexcitability and Tactile Allodynia in Male and Female Neuropathic Mice,” Iscience 26 (2023): 108110.

[185] J. Lee, H. Hwang, and S. J. Lee, “Distinct Roles of GT1b and CSF-1 in Microglia Activation in Nerve Injury-induced Neuropathic Pain,” Molecular Pain 17 (2021): 17448069211020918.

[186] L. Yang, A. Gomm, P. Bai, et al., “The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice,” Anesthesia and Analgesia 141 (2025): 199–209.

[187] Y. Zheng, J. Zhao, S. Chang, et al., “β-Sitosterol Alleviates Neuropathic Pain by Affect Microglia Polarization Through Inhibiting TLR4/NF-κB Signaling Pathway,” Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology 18 (2023): 690–703.

[188] C. A. Warwick, A. L. Keyes, T. M. Woodruff, and Y. M. Usachev, “The Complement Cascade in the Regulation of Neuroinflammation, Nociceptive Sensitization, and Pain,” The Journal of Biological Chemistry 297 (2021): 101085.

[189] W. Mou, L. Ma, A. Zhu, H. Cui, and Y. Huang, “Astrocyte-microglia Interaction Through C3/C3aR Pathway Modulates Neuropathic Pain in Rats Model of Chronic Constriction Injury,” Molecular Pain 18 (2022): 17448069221140532.

[190] X. Wei, X. Jin, X. Meng, et al., “Platelet-rich Plasma Improves Chronic Inflammatory Pain by Inhibiting PKM2-mediated Aerobic Glycolysis in Astrocytes,” Annals of Translational Medicine 8 (2020): 1456.

[191] X. Fan, S. Zhang, S. Sun, et al., “GFAP Palmitoylcation Mediated by ZDHHC23 in Spinal Astrocytes Contributes to the Development of Neuropathic Pain,” Regional Anesthesia & Pain Medicine 49 (2024): 821–830.

[192] T. L. Hagemann, S. Coyne, A. Levin, L. Wang, M. B. Feany, and A. Messing, “STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease,” Cells-Basel 12 (2023): 978.

[193] R. Luo, X. Hu, X. Li, et al., “Dysfunctional Astrocyte Glutamate Uptake in the Hypothalamic Paraventricular Nucleus Contributes to Visceral Pain and Anxiety-Like Behavior in Mice With Chronic Pancreatitis,” Glia 72 (2024): 2022–2037.

[194] J. Tang, M. Bair, and G. Descalzi, “Reactive Astrocytes: Critical Players in the Development of Chronic Pain,” Frontiers in Psychiatry 12 (2021): 682056.

[195] X. Song, C. Yang, D. Chen, et al., “Up-regulation of LCN2 in the Anterior Cingulate Cortex Contributes to Neural Injury-induced Chronic Pain,” Frontiers in Cellular Neuroscience 17 (2023): 1140769.

[196] S. Lee, J. Kim, J. Kim, et al., “Lipocalin-2 Is a Chemokine Inducer in the central Nervous System: Role of Chemokine Ligand 10 (CXCL10) in Lipocalin-2-induced Cell Migration,” The Journal of Biological Chemistry 286 (2011): 43855–43870.

[197] S. Jeon, M. K. Jha, J. Ock, et al., “Role of Lipocalin-2-chemokine Axis in the Development of Neuropathic Pain Following Peripheral Nerve Injury,” The Journal of Biological Chemistry 288 (2013): 24116–24127.

[198] M. K. Jha, S. Lee, D. H. Park, et al., “Diverse Functional Roles of Lipocalin-2 in the central Nervous System,” Neuroscience & Biobehavioral Reviews 49 (2015): 135–156.

[199] H. Lu and Y. Gao, “Astrocytes in Chronic Pain: Cellular and Molecular Mechanisms,” Neuroscience Bulletin 39 (2023): 425–439.

[200] J. A. Kuhn, I. D. Vainchtein, J. Braz, et al., “Regulatory T-cells Inhibit Microglia-induced Pain Hypersensitivity in Female Mice,” Elife 10 (2021): e69056.

[201] J. Sun, W. Dai, X. Shen, N. Lü, and Y. Zhang, “Interleukin-17 Is Involved in Neuropathic Pain and Spinal Synapse Plasticity on Mice,” Journal of Neuroimmunology 377 (2023): 578068.

[202] X. Zhu, X. Li, S. Liu, et al., “Enhanced Interleukin-16-CD4 Signaling in CD3 T Cell Mediates Neuropathic Pain via Activating Astrocytes in Female Mice,” Neuropharmacology 259 (2024): 110115.

[203] L. Huang, J. Jin, K. Chen, et al., “BDNF Produced by Cerebral Microglia Promotes Cortical Plasticity and Pain Hypersensitivity After Peripheral Nerve Injury,” Plos Biology 19 (2021): e3001337.

[204] F. Saika, Y. Fukazawa, Y. Hatano, et al., “Sexually Dimorphic Effects of pexidartinib on Nerve Injury-induced Neuropathic Pain in Mice,” Glia 72 (2024): 1402–1417.

[205] R. Domoto, F. Sekiguchi, M. Tsubota, and A. Kawabata, “Macrophage as a Peripheral Pain Regulator,” Cells-Basel 10 (2021): 1881.

[206] X. Yu, H. Liu, K. A. Hamel, et al., “Dorsal Root Ganglion Macrophages Contribute to both the Initiation and Persistence of Neuropathic Pain,” Nature Communications 11 (2020): 264.

[207] J. A. Liu, J. Yu, and C. W. Cheung, “Immune Actions on the Peripheral Nervous System in Pain,” International Journal of Molecular Sciences 22 (2021): 1448.

[208] H. Zhang, Y. Li, M. de Carvalho-Barbosa, et al., “Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy,” The Journal of Pain 17 (2016): 775–786.

[209] M. van der Vlist, R. Raoof, H. Willemen, et al., “Macrophages Transfer Mitochondria to Sensory Neurons to Resolve Inflammatory Pain,” Neuron 110 (2022): 613–626.

[210] M. Dansereau, É. Midavaine, V. Bégin-Lavallée, et al., “Mechanistic Insights Into the Role of the Chemokine CCL2/CCR2 Axis in Dorsal Root Ganglia to Peripheral Inflammation and Pain Hypersensitivity,” Journal of Neuroinflammation 18 (2021): 79.

[211] U. Cuhadar, C. Gentry, N. Vastani, et al., “Autoantibodies Produce Pain in Complex Regional Pain Syndrome by Sensitizing Nociceptors,” Pain 160 (2019): 2855–2865.

[212] Z. Helyes, V. Tékus, N. Szentes, et al., “Transfer of Complex Regional Pain Syndrome to Mice via human Autoantibodies Is Mediated by Interleukin-1-induced Mechanisms,” Proceedings of the National Academy of Sciences of the United States of America 116 (2019): 13067–13076.

[213] A. Goebel, D. Andersson, Z. Helyes, J. D. Clark, D. Dulake, and C. Svensson, “The Autoimmune Aetiology of Unexplained Chronic Pain,” Autoimmunity Reviews 21 (2022): 103015.

[214] K. H. Barker, J. P. Higham, L. A. Pattison, et al., “Sensitization of Colonic Nociceptors by TNFα Is Dependent on TNFR1 Expression and p38 MAPK Activity,” The Journal of Physiology 600 (2022): 3819–3836.

[215] P. A. Boakye, S. Tang, and P. A. Smith, “Mediators of Neuropathic Pain; Focus on Spinal Microglia, CSF-1, BDNF, CCL21, TNF-α, Wnt Ligands, and Interleukin 1β,” Frontiers in Pain Research (Lausanne, Switzerland) 2 (2021): 698157.

[216] J. Zhao, Y. Huh, A. Bortsov, L. Diatchenko, and R. Ji, “Immunotherapies in Chronic Pain Through Modulation of Neuroimmune Interactions,” Pharmacology and Therapeutics 248 (2023): 108476.

[217] Q. Li, Z. Yang, K. Wang, Z. Chen, and H. Shen, “Suppression of Microglial Ccl2 Reduces Neuropathic Pain Associated With Chronic Spinal Compression,” Frontiers in Immunology 14 (2023): 1191188.

[218] A. Bober, A. Piotrowska, K. Pawlik, et al., “A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model,” International Journal of Molecular Sciences 25 (2024): 7410.

[219] F. Gao, M. Wei, M. Wang, et al., “The Role and Mechanism of Spinal NF-κB-CXCL1/CXCR2 in Rats With Nucleus Pulposus-induced Radicular Pain,” Spine 49 (2024): E87–99.

[220] F. Yang, W. Sun, Y. Yang, et al., “SDF1-CXCR4 signaling Contributes to Persistent Pain and Hypersensitivity via Regulating Excitability of Primary Nociceptive Neurons: Involvement of ERK-dependent Nav1.8 Up-regulation,” Journal of Neuroinflammation 12 (2015): 219.

[221] H. Xu, C. Peng, X. Chen, et al., “Chemokine Receptor CXCR4 Activates the RhoA/ROCK2 Pathway in Spinal Neurons That Induces Bone Cancer Pain,” Molecular Pain 16 (2020): 1744806920919568.

[222] X. Luo, X. Wang, Z. Xia, S. K. Chung, and C. W. Cheung, “CXCL12/CXCR4 axis: An Emerging Neuromodulator in Pathological Pain,” Reviews in the Neurosciences 27 (2016): 83–92.

[223] C. Wang, Q. Yin, Z. Su, and L. Xia, “Progress on Role of Extracellular ATP and Its Metabolite Adenosine in Immunoregulation: Review,” Xi bao yu fen zi mian yi xue za zhi = Chinese Journal of Cellular and Molecular Immunology 36 (2020): 1134–1140.

[224] K. Inoue, “The Role of ATP Receptors in Pain Signaling,” Neurochemical Research 47 (2022): 2454–2468.

[225] H. Tozaki-Saitoh, H. Takeda, and K. Inoue, “The Role of Microglial Purinergic Receptors in Pain Signaling,” Molecules (Basel, Switzerland) 27 (2022): 1919.

[226] W. Ren and P. Illes, “Involvement of P2×7 Receptors in Chronic Pain Disorders,” Purinergic Signaling 18 (2022): 83–92.

[227] M. F. Muñoz, T. N. Griffith, and J. E. Contreras, “Mechanisms of ATP Release in Pain: Role of Pannexin and Connexin Channels,” Purinergic Signaling 17 (2021): 549–561.

[228] M. Okada and T. Nose, “Eperisone Hydrochloride, a Muscle Relaxant, Is a Potent P2×7 Receptor Antagonist,” Chemical and Pharmaceutical Bulletin 72 (2024): 345–348.

[229] C. Nwebube, S. Bulancea, A. Marchidann, L. Bello-Espinosa, and Treidler S, “Erythromelalgia: A Child With V400M Mutation in the SCN9A Gene,” Neurology Genetics 7 (2021): e570.

[230] M. Yang, R. E. Baser, R. Khanin, et al., “COMT Val158Met Affects the Analgesic Response to Acupuncture among Cancer Survivors with Chronic Pain,” The Journal of Pain 24 (2023): 1721–1730.

[231] P. Hsu, C. Liu, C. Yang, et al., “Reward System Neurodynamics During Menstrual Pain Modulated by COMT Val158Met Polymorphisms,” Frontiers in Molecular Neuroscience 17 (2024): 1457602.

[232] E. A. Trimble, P. A. Kell, M. A. Avella, C. R. France, and J. L. Rhudy, “Opioid Receptor Mu 1 Gene (OPRM1) A118G Polymorphism and Emotional Modulation of Pain,” Journal of Pain Research 17 (2024): 489–500.

[233] H. Zhang, C. Wang, K. Zhang, et al., “The Role of TRPA1 Channels in Thermosensation,” Cell Insight 1 (2022): 100059.

[234] E. Mocci, K. Ward, J. A. Perry, et al., “Genome Wide Association Joint Analysis Reveals 99 Risk Loci for Pain Susceptibility and Pleiotropic Relationships With Psychiatric, Metabolic, and Immunological Traits,” PLos Genetics 19 (2023): e1010977.

[235] K. J. A. Johnston, J. Ward, P. R. Ray, et al., “Sex-stratified Genome-wide Association Study of Multisite Chronic Pain in UK Biobank,” PLos Genetics 17 (2021): e1009428.

[236] Y. A. Tsepilov, E. E. Elgaeva, A. V. Nostaeva, et al., “Development and Replication of a Genome-Wide Polygenic Risk Score for Chronic Back Pain,” Journal of Personalized Medicine 13 (2023): 977.

[237] K. Zorina-Lichtenwalter, C. I. Bango, L. Van Oudenhove, et al., “Genetic Risk Shared Across 24 Chronic Pain Conditions: Identification and Characterization With Genomic Structural Equation Modeling,” Pain 164 (2023): 2239–2252.

[238] D. Mauceri, “Role of Epigenetic Mechanisms in Chronic Pain,” Cells-Basel 11 (2022): 2613.

[239] G. Pethő, B. Kántás, Á. Horváth, and E. Pintér, “The Epigenetics of Neuropathic Pain: A Systematic Update,” International Journal of Molecular Sciences 24 (2023): 17143.

[240] W. Jiang, X. Tan, J. Li, P. Yu, and M. Dong, “DNA Methylation: A Target in Neuropathic Pain,” Frontiers in Medicine-Lausanne 9 (2022): 879902.

[241] K. Sun, H. Zhang, T. Zhang, et al., “Spinal HDAC6 Mediates Nociceptive Behaviors Induced by Chronic Constriction Injury via Neuronal Activation and Neuroinflammation,” Molecular Pain 19 (2023): 17448069231218352.

[242] J. Zhang, S. Chen, M. Zhou, et al., “HDAC2 in Primary Sensory Neurons Constitutively Restrains Chronic Pain by Repressing α2δ-1 Expression and Associated NMDA Receptor Activity,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 42 (2022): 8918–8935.

[243] H. Weng, K. Taing, L. Chen, and A. Penney, “EZH2 Methyltransferase Regulates Neuroinflammation and Neuropathic Pain,” Cells-Basel 12 (2023): 1058.

[244] S. Sabina, A. Panico, P. Mincarone, et al., “Expression and Biological Functions of miRNAs in Chronic Pain: A Review on Human Studies,” International Journal of Molecular Sciences 23 (2022): 6016.

[245] J. Roganović and N. Petrović, “Clinical Perspectives of Non-Coding RNA in Oral Inflammatory Diseases and Neuropathic Pain: A Narrative Review,” International Journal of Molecular Sciences 23 (2022): 8278.

[246] M. Morchio, E. Sher, D. A. Collier, D. W. Lambert, and F. M. Boissonade, “The Role of miRNAs in Neuropathic Pain,” Biomedicines 11 (2023): 775.

[247] L. Zeboudj, G. Sideris-Lampretsas, R. Silva, et al., “Silencing miR-21-5p in Sensory Neurons Reverses Neuropathic Allodynia via Activation of TGF-β-related Pathway in Macrophages,” The Journal of Clinical Investigation 133 (2023): e164472.

[248] Z. Li, X. Li, W. Jian, Q. Xue, and Z. Liu, “Roles of Long Non-coding RNAs in the Development of Chronic Pain,” Frontiers in Molecular Neuroscience 14 (2021): 760964.

[249] K. Zhang, P. Li, Y. Jia, M. Liu, and J. Jiang, “Non-coding RNA and n6-methyladenosine Modification Play Crucial Roles in Neuropathic Pain,” Frontiers in Molecular Neuroscience 15 (2022): 1002018.

[250] Z. Pan, Q. Zhang, X. Liu, et al., “Methyltransferase-Like 3 Contributes to Inflammatory Pain by Targeting TET1 in YTHDF2-dependent Manner,” Pain 162 (2021): 1960–1976.

[251] W. Lu, X. Yang, W. Zhong, et al., “METTL14-mediated m6A Epitranscriptomic Modification Contributes to Chemotherapy-induced Neuropathic Pain by Stabilizing GluN2A Expression via IGF2BP2,” The Journal of Clinical Investigation 134 (2024): e174847.

[252] C. Zhang, R. Gao, R. Zhou, et al., “The Emerging Power and Promise of Non-coding RNAs in Chronic Pain,” Frontiers in Molecular Neuroscience 15 (2022): 1037929.

[253] M. V. Centeno, M. S. Alam, K. Haldar, and A. V. Apkarian, “Long-range action of an HDAC inhibitor treats chronic pain in a spared nerve injury rat model,” bioRxiv: The Preprint Server for Biology (2023): 2012–2023.

[254] R. Cai, R. Lv, X. Shi, G. Yang, and J. Jin, “CRISPR/dCas9 Tools: Epigenetic Mechanism and Application in Gene Transcriptional Regulation,” International Journal of Molecular Sciences 24 (2023): 14865.

[255] E. Knezevic, K. Nenic, V. Milanovic, and N. N. Knezevic, “The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders,” Cells-Basel 12 (2023): 2726.

[256] M. Armstrong, J. Castellanos, and D. Christie, “Chronic Pain as an Emergent Property of a Complex System and the Potential Roles of Psychedelic Therapies,” Frontiers in Pain Research (Lausanne, Switzerland) 5 (2024): 1346053.

[257] A. Waisman and J. Katz, “The Autobiographical Memory System and Chronic Pain: A Neurocognitive Framework for the Initiation and Maintenance of Chronic Pain,” Neuroscience and Biobehavioral Reviews 162 (2024): 105736.

[258] E. Wojtyna, M. Hyla, and A. Hachuła, “Pain of Threatened Self: Explicit and Implicit Self-Esteem, Cortisol Responses to a Social Threat and Pain Perception,” Journal of Clinical Medicine 13 (2024): 2705.

[259] M. Zhu and H. Huang, “The Underlying Mechanisms of Sleep Deprivation Exacerbating Neuropathic Pain,” Nature and Science of Sleep 15 (2023): 579–591.

[260] M. Haack, E. Sanchez, and J. M. Mullington, “Elevated Inflammatory Markers in Response to Prolonged Sleep Restriction Are Associated With Increased Pain Experience in Healthy Volunteers,” Sleep 30 (2007): 1145–1152.

[261] M. Jepma, M. Roy, K. Ramlakhan, M. van Velzen, and A. Dahan, “Different Brain Systems Support Learning From Received and Avoided Pain During human Pain-avoidance Learning,” Elife 11 (2022): e74149.

[262] Y. Shi, S. Cui, Y. Zeng, et al., “Brain Network to Placebo and Nocebo Responses in Acute Experimental Lower Back Pain: A Multivariate Granger Causality Analysis of fMRI Data,” Frontiers in Behavioral Neuroscience 15 (2021): 696577.

[263] J. L. Aulenkamp, A. Icenhour, and S. Elsenbruch, “Nocebo Effects in Visceral Pain: Concept and Design of the Experimental Randomized-controlled Pain Study ‘NoVis’,” Frontiers in Psychiatry 14 (2023): 1270189.

[264] C. Chuang, J. Li, J. King, et al., “Abnormal Heart Rate Variability and Its Application in Predicting Treatment Efficacy in Patients With Chronic Migraine: An Exploratory Study,” Cephalalgia: An International Journal of Headache 43 (2023): 3331024231206781.

[265] T. Meus, J. Van Eetvelde, I. Meuwissen, et al., “Exercise and Heart Rate Variability in Chronic Musculoskeletal Pain: A Systematic Review,” Sports Medicine - Open 11 (2025): 109.

[266] P. Xu, H. R. Fan, E. M. Zhang, H. N. Zhang, and Y. Fei, “Advances in the Treatment of Neuropathic Pain by Sympathetic Regulation,” Current Pain and Headache Reports 28 (2024): 1167–1176.

[267] H. Liu, X. Zhang, P. Shi, et al., “α7 Nicotinic Acetylcholine Receptor: A Key Receptor in the Cholinergic Anti-inflammatory Pathway Exerting an Antidepressant Effect,” Journal of Neuroinflammation 20 (2023): 84.

[268] C. Zhang, H. Xu, H. Zheng, X. Wu, H. Du, and X. Jin, “Assessing the Viability of Heart Rate Variability as an Objective and Comprehensive Indicator of Chronic Non-specific Neck Pain,” PLoS ONE 20 (2025): e0326357.

[269] V. Costa, A. C. Gianlorenço, M. F. Andrade, et al., “Transcutaneous Vagus Nerve Stimulation Effects on Chronic Pain: Systematic Review and Meta-analysis,” PAIN Reports 9 (2024): e1171.

[270] A. N. H. Gerges, E. E. R. Williams, S. Hillier, et al., “Clinical Application of Transcutaneous Auricular Vagus Nerve Stimulation: A Scoping Review,” Disability and Rehabilitation 46 (2024): 5730–5760.

[271] G. Magni, B. Riboldi, and S. Ceruti, “Modulation of Glial Cell Functions by the Gut-Brain Axis: A Role in Neurodegenerative Disorders and Pain Transmission,” Cells-Basel 12 (2023): 1612.

[272] C. Garofalo, C. M. Cristiani, S. Ilari, et al., “Fibromyalgia and Irritable Bowel Syndrome Interaction: A Possible Role for Gut Microbiota and Gut-Brain Axis,” Biomedicines 11 (2023): 1701.

[273] J. Pujo, G. De Palma, J. Lu, et al., “Gut Microbiota Modulates Visceral Sensitivity Through Calcitonin Gene-related Peptide (CGRP) Production,” Gut Microbes 15 (2023): 2188874.

[274] A. V. Colombo, R. K. Sadler, G. Llovera, et al., “Microbiota-derived Short Chain Fatty Acids Modulate Microglia and Promote Aβ Plaque Deposition,” Elife 10 (2021): e59826.

[275] F. Zhou, X. Wang, B. Han, et al., “Short-chain Fatty Acids Contribute to Neuropathic Pain via Regulating Microglia Activation and Polarization,” Molecular Pain 17 (2021): 1744806921996520.

[276] L. Goudman, T. Demuyser, J. G. Pilitsis, et al., “Gut Dysbiosis in Patients With Chronic Pain: A Systematic Review and Meta-analysis,” Frontiers in Immunology 15 (2024): 1342833.

[277] K. P. Nicolson, S. E. E. Mills, D. N. S. Senaratne, L. A. Colvin, and B. H. Smith, “What Is the Association Between Childhood Adversity and Subsequent Chronic Pain in Adulthood?,” A Systematic Review BJA Open 6 (2023): 100139.

[278] G. Antoniou, E. Lambourg, J. D. Steele, and L. A. Colvin, “The Effect of Adverse Childhood Experiences on Chronic Pain and Major Depression in Adulthood: A Systematic Review and Meta-analysis,” British Journal of Anaesthesia 130 (2023): 729–746.

[279] J. Christensen, J. K. Beveridge, M. Wang, S. L. Orr, M. Noel, and R. Mychasiuk, “A Pilot Study Investigating the Role of Gender in the Intergenerational Relationships Between Gene Expression, Chronic Pain, and Adverse Childhood Experiences in a Clinical Sample of Youth With Chronic Pain,” Epigenomes 5 (2021): 9.

[280] A. P. Vu, D. Lam, C. Denney, K. V. Lee, J. R. Plemel, and J. Jackson, “Social Isolation Produces a Sex- and Brain Region-specific Alteration of Microglia state,” The European Journal of Neuroscience 57 (2023): 1481–1497.

[281] T. K. M. Cudjoe, S. Selvakumar, S. Chung, et al., “Getting Under the Skin: Social Isolation and Biological Markers in the National Health and Aging Trends Study,” Journal of the American Geriatrics Society 70 (2022): 408–414.

[282] R. Rogger, C. Bello, C. S. Romero, R. D. Urman, M. M. Luedi, and M. G. Filipovic, “Cultural Framing and the Impact on Acute Pain and Pain Services,” Current Pain and Headache Reports 27 (2023): 429–436.

[283] I. Kovačević, J. Pavić, B. Filipović, Š. Ozimec Vulinec, B. Ilić, and D. Petek, “Integrated Approach to Chronic Pain-The Role of Psychosocial Factors and Multidisciplinary Treatment: A Narrative Review,” International Journal of Environmental Research and Public Health 21 (2024): 1135.

[284] A. Lampert, D. L. Bennett, L. A. McDermott, et al., “Human Sensory Neurons Derived From Pluripotent Stem Cells for Disease Modelling and Personalized Medicine,” Neurobiology of Pain (Cambridge, Mass) 8 (2020): 100055.

[285] M. Alsaloum, J. I. R. Labau, S. Liu, P. R. Effraim, and S. G. Waxman, “Stem Cell-derived Sensory Neurons Modelling Inherited Erythromelalgia: Normalization of Excitability,” Brain: A Journal of Neurology 146 (2023): 359–371.

[286] S. Giorgi, A. Lamberti, L. Butrón, et al., “Compartmentalized Primary Cultures of Dorsal Root Ganglion Neurons to Model Peripheral Pathophysiological Conditions,” Molecular Pain 19 (2023): 17448069231197102.

[287] K. Xie, X. Cheng, T. Zhu, and D. Zhang, “Single-cell Transcriptomic Profiling of Dorsal Root Ganglion: An Overview,” Frontiers in Neuroanatomy 17 (2023): 1162049.

[288] Erratum for the Research Resource: “Harmonized Cross-species Cell Atlases of Trigeminal and Dorsal Root Ganglia” by S. Bhuiyan et al. Science Advances 2024; 10: eadt4792.

[289] D. Zhang, Y. Chen, Y. Wei, et al., “Spatial Transcriptomics and Single-nucleus RNA Sequencing Reveal a Transcriptomic Atlas of Adult human Spinal Cord,” Elife 12 (2024): RP92046.

[290] J. Shannonhouse, R. Gomez, H. Son, Y. Zhang, and Y. S. Kim, “In Vivo Calcium Imaging of Neuronal Ensembles in Networks of Primary Sensory Neurons in Intact Dorsal Root Ganglia,” JoVE: Journal of Visualized Experiments 192 (2023): 10–3791.

[291] M. Yi, Y. U. Liu, A. D. Umpierre, et al., “Optogenetic Activation of Spinal Microglia Triggers Chronic Pain in Mice,” Plos Biology 19 (2021): e3001154.

[292] E. K. Serafin, J. J. Yoo, J. Li, X. Dong, and M. L. Baccei, “Development and Characterization of a Gucy2d-cre Mouse to Selectively Manipulate a Subset of Inhibitory Spinal Dorsal Horn Interneurons,” PLoS ONE 19 (2024): e0300282.

[293] J. M. Hagedorn, J. Gunn, R. Budwany, R. S. D'Souza, K. Chakravarthy, and T. R. Deer, “How Well Do Current Laboratory Biomarkers Inform Clinical Decision-Making in Chronic Pain Management?,” Journal of Pain Research 14 (2021): 3695–3710.

[294] M. A. Kelley and K. V. Hackshaw, “Intraepidermal Nerve Fiber Density as Measured by Skin Punch Biopsy as a Marker for Small Fiber Neuropathy: Application in Patients With Fibromyalgia,” Diagnostics 11 (2021): 536.

[295] K. R. Weaver, M. A. Griffioen, N. J. Klinedinst, et al., “Quantitative Sensory Testing across Chronic Pain Conditions and Use in Special Populations,” Frontiers in Pain Research (Lausanne, Switzerland) 2 (2022): 779068.

[296] M. V. Lukashenko, N. Y. Gavrilova, A. V. Bregovskaya, et al., “Corneal Confocal Microscopy in the Diagnosis of Small Fiber Neuropathy: Faster, Easier, and More Efficient than Skin Biopsy?,” Pathophysiology: The Official Journal of the International Society for Pathophysiology 29 (2021): 1–8.

[297] A. Rhee, I. Granville Smith, R. Compte, et al., “Quantitative Sensory Testing and Chronic Pain Syndromes: A Cross-sectional Study From TwinsUK,” Bmj Open 14 (2024): e085814.

[298] K. K. Petersen, H. B. Vaegter, A. Stubhaug, et al., “The Predictive Value of Quantitative Sensory Testing: A Systematic Review on Chronic Postoperative Pain and the Analgesic Effect of Pharmacological Therapies in Patients With Chronic Pain,” Pain 162 (2021): 31–44.

[299] Y. Hung, C. Chou, Y. Yang, H. Fu, E. Loh, and H. Kang, “Exosomal let-7e, miR-21-5p, miR-145, miR-146a and miR-155 in Predicting Antidepressants Response in Patients with Major Depressive Disorder,” Biomedicines 9 (2021): 1428.

[300] D. Martins, M. Veronese, F. E. Turkheimer, M. A. Howard, S. C. R. Williams, and O. Dipasquale, “A Candidate Neuroimaging Biomarker for Detection of Neurotransmission-related Functional Alterations and Prediction of Pharmacological Analgesic Response in Chronic Pain,” Brain Communications 4 (2021): fcab302.

[301] E. Fisher, G. Villanueva, N. Henschke, et al., “Efficacy and Safety of Pharmacological, Physical, and Psychological Interventions for the Management of Chronic Pain in Children: A WHO Systematic Review and Meta-analysis,” Pain 163 (2022): e1–19.

[302] F. Zmudzki, R. Smeets, J. S. Groenewegen, and E. van der Graaff, “Machine Learning Clinical Decision Support for Interdisciplinary Multimodal Chronic Musculoskeletal Pain Treatment: Prospective Pilot Study of Patient Assessment and Prognostic Profile Validation,” JMIR Rehabilitation and Assistive Technologies 12 (2025): e65890.

[303] R. Sohail, M. Mathew, K. K. Patel, et al., “Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review,” Cureus: Journal of Medical Science 15 (2023): e37080.

[304] J. Ton, D. Perry, B. Thomas, et al., “PEER Umbrella Systematic Review of Systematic Reviews: Management of Osteoarthritis in Primary Care,” Canadian Family Physician Medecin de Famille Canadien 66 (2020): e89–98.

[305] N. Arora, A. Kumar, A. Kumar, and R. S. Sharma, “Chronic Pain Management during a Pandemic: Evidence-Based Review,” Turkish Journal of Anaesthesiology 50 (2022): 159–166.

[306] C. Mallet, J. Desmeules, R. Pegahi, and A. Eschalier, “An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact,” Journal of Pain Research 16 (2023): 1081–1094.

[307] N. Ohashi and T. Kohno, “Analgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action,” Frontiers in Pharmacology 11 (2020): 580289.

[308] F. Silva, G. Costa, F. Veiga, C. Cardoso, and A. C. Paiva-Santos, “Parenteral Ready-to-Use Fixed-Dose Combinations Including NSAIDs With Paracetamol or Metamizole for Multimodal Analgesia-Approved Products and Challenges,” Pharmaceuticals-Base 16 (2023): 1084.

[309] M. C. Gamble, B. R. Williams, N. Singh, et al., “Mu-opioid Receptor and Receptor Tyrosine Kinase Crosstalk: Implications in Mechanisms of Opioid Tolerance, Reduced Analgesia to Neuropathic Pain, Dependence, and Reward,” Frontiers in Systems Neuroscience 16 (2022): 1059089.

[310] A. K. Paul, C. M. Smith, M. Rahmatullah, et al., “Opioid Analgesia and Opioid-Induced Adverse Effects: A Review,” Pharmaceuticals-Base 14 (2021): 1091.

[311] K. E. Vowles, M. L. McEntee, P. S. Julnes, T. Frohe, J. P. Ney, and D. N. van der Goes, “Rates of Opioid Misuse, Abuse, and Addiction in Chronic Pain: A Systematic Review and Data Synthesis,” Pain 156 (2015): 569–576.

[312] D. Dowell, K. R. Ragan, C. M. Jones, G. T. Baldwin, and R. Chou, “CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022,” MMWR Recommendations and Reports: Morbidity and Mortality Weekly Report Recommendations and Reports 71 (2022): 1–95.

[313] M. Niesters, A. Dahan, B. Kest, et al., “Do Sex Differences Exist in Opioid Analgesia? A Systematic Review and Meta-analysis of human Experimental and Clinical Studies,” Pain 151 (2010): 61–68.

[314] T. Günther, P. Dasgupta, A. Mann, et al., “Targeting Multiple Opioid Receptors—improved Analgesics With Reduced Side Effects?,” British Journal of Pharmacology 175 (2018): 2857–2868.

[315] T. Roth, R. van Seventer, and T. K. Murphy, “The Effect of Pregabalin on Pain-related Sleep Interference in Diabetic Peripheral Neuropathy or Postherpetic Neuralgia: A Review of Nine Clinical Trials,” Current Medical Research and Opinion 26 (2010): 2411–2419.

[316] H. Birkinshaw, C. M. Friedrich, P. Cole, et al., “Antidepressants for Pain Management in Adults With Chronic Pain: A Network Meta-analysis,” Cochrane Database of Systematic Reviews 5 (2023): CD014682.

[317] D. Rodrigues-Amorim, J. M. Olivares, C. Spuch, and T. Rivera-Baltanás, “A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine,” Frontiers in Psychiatry 11 (2020): 554899.

[318] B. Chen, J. Duan, S. Wen, et al., “An Updated Systematic Review and Meta-analysis of Duloxetine for Knee Osteoarthritis Pain,” The Clinical Journal of Pain 37 (2021): 852–862.

[319] Y. Lian, Y. Wang, Y. Zhang, and C. Yang, “Duloxetine for Pain in Fibromyalgia in Adults: A Systematic Review and a Meta-analysis,” The International Journal of Neuroscience 130 (2020): 71–82.

[320] A. Qaseem, T. J. Wilt, R. M. McLean, et al., “Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline from the American College of Physicians,” Annals of Internal Medicine 166 (2017): 514–530.

[321] R. B. Fillingim, C. D. King, M. C. Ribeiro-Dasilva, B. Rahim-Williams, and J. L. Riley, “Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings,” The Journal of Pain 10 (2009): 447–485.

[322] N. M. Alorfi, “Pharmacological Methods of Pain Management: Narrative Review of Medication Used,” International Journal of General Medicine 16 (2023): 3247–3256.

[323] C. S. Wright, A. N. Masterson, et al., “Gabapentin Disrupts Binding of Perlecan to the α(2)δ(1) Voltage Sensitive Calcium Channel Subunit and Impairs Skeletal Mechanosensation,” Biomolecules 12 (2022): 1857.

[324] M. Davari, B. Amani, B. Amani, A. Khanijahani, A. Akbarzadeh, and R. Shabestan, “Pregabalin and Gabapentin in Neuropathic Pain Management After Spinal Cord Injury: A Systematic Review and Meta-analysis,” Korean Journal of Pain 33 (2020): 3–12.

[325] S. Derry, R. F. Bell, S. Straube, P. J. Wiffen, D. Aldington, and R. A. Moore, “Pregabalin for Neuropathic Pain in Adults,” Cochrane Database of Systematic Reviews 1 (2019): CD007076.

[326] J. H. Atkinson, M. A. Slater, E. V. Capparelli, et al., “A Randomized Controlled Trial of gabapentin for Chronic Low Back Pain With and Without a Radiating Component,” Pain 157 (2016): 1499–1507.

[327] P. J. Wiffen, S. Derry, R. F. Bell, et al., “Gabapentin for Chronic Neuropathic Pain in Adults,” Cochrane Database of Systematic Reviews 6 (2017): CD007938.

[328] M. A. Corriere, L. L. Daniel, A. L. Dickson, et al., “Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients With Non-Cancer Pain,” Clinical Pharmacology and Therapeutics 114 (2023): 1050–1057.

[329] T. Gomes, D. N. Juurlink, T. Antoniou, M. M. Mamdani, J. M. Paterson, and W. van den Brink, “Gabapentin, Opioids, and the Risk of Opioid-related Death: A Population-based Nested Case-control Study,” Plos Medicine 14 (2017): e1002396.

[330] M. Zhang, C. Gao, K. Ma, et al., “A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia From Randomized Controlled Trials,” BioMed Research International 2018 (2018): 7474207.

[331] O. Enke, H. A. New, C. H. New, et al., “Anticonvulsants in the Treatment of Low Back Pain and Lumbar Radicular Pain: A Systematic Review and Meta-analysis,” CMAJ: Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne 190 (2018): E786–E793.

[332] S. Jinesh, “Pharmaceutical Aspects of Novel CGRP Inhibitors Used in the Prophylaxis and Treatment of Migraine,” Inflammopharmacology 31 (2023): 2245–2251.

[333] R. B. Lipton, D. W. Dodick, J. Ailani, et al., “Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial,” Jama-Journal of the American Medical Association 322 (2019): 1887–1898.

[334] R. B. Lipton, R. Croop, E. G. Stock, et al., “Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine,” The New England Journal of Medicine 381 (2019): 142–149.

[335] I. Troussier, C. Canova, and G. Klausner, “Complete Response of Leptomeningeal Carcinomatosis Secondary to Breast Cancer,” Breast (Edinburgh, Scotland) (Edinburgh, Scotland) 54 (2020): 328–330.

[336] D. Xue, D. Yao, R. K. Sukumaran, X. You, Z. Wei, and C. Gong, “Tandem Integration of Aerobic Fungal Cellulase Production, Lignocellulose Substrate Saccharification and anaerobic Ethanol Fermentation by a Modified Gas Lift Bioreactor,” Bioresource Technology 302 (2020): 122902.

[337] Vascular Safety of erenumab for Migraine Prevention. Neurology 2020; 94: 1052.

[338] H. Mo, B. Kim, H. Moon, and S. Cho, “Real-world Experience With 240 mg of Galcanezumab for the Preventive Treatment of Cluster Headache,” The Journal of Headache and Pain 23 (2022): 132.

[339] J. Perino, V. Corand, E. Laurent, et al., “Myocardial Infarction Associated With erenumab: A Case Report,” Pharmacotherapy 42 (2022): 585–589.

[340] P. A. Barker, P. Mantyh, L. Arendt-Nielsen, L. Viktrup, and L. Tive, “Nerve Growth Factor Signaling and Its Contribution to Pain,” Journal of Pain Research 13 (2020): 1223–1241.

[341] F. Berenbaum, F. J. Blanco, A. Guermazi, et al., “Subcutaneous tanezumab for Osteoarthritis of the Hip or Knee: Efficacy and Safety Results From a 24-week Randomised Phase III Study With a 24-week Follow-up Period,” Annals of the Rheumatic Diseases 79 (2020): 800–810.

[342] L. Zhao, Y. Lai, H. Jiao, and J. Huang, “Nerve Growth Factor Receptor Limits Inflammation to Promote Remodeling and Repair of Osteoarthritic Joints,” Nature Communications 15 (2024): 3225.

[343] Y. Yu, S. Lu, J. Sun, and W. Zhou, “Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials,” Pain Medicine (Malden, Mass) 22 (2021): 585–595.

[344] B. W. Dietz, M. C. Nakamura, M. T. Bell, and N. E. Lane, “Targeting Nerve Growth Factor for Pain Management in Osteoarthritis-Clinical Efficacy and Safety,” Rheumatic Diseases Clinics of North America 47 (2021): 181–195.

[345] Y. Kitano and T. Shinozuka, “Inhibition of Na(V)1.7: The Possibility of Ideal Analgesics,” RSC Medicinal Chemistry 13 (2022): 895–920.

[346] K. Kingwell, “Nav1.7 withholds Its Pain Potential,” Nature Reviews Drug Discovery 18 (2019): 10–1038.

[347] M. Alves-Simões, L. Teege, C. Tomni, et al., “Na V 1.8/Na V 1.9 Double Deletion Mildly Affects Acute Pain Responses in Mice,” Pain 166 (2025): 773–792.

[348] F. Yuan, F. Sun, L. Zhang, et al., “General Mechanism of Spider Toxin family I Acting on Sodium Channel Nav1.7,” Zoological Research 43 (2022): 886–896.

[349] J. M. Zakrzewska, J. Palmer, V. Morisset, et al., “Safety and Efficacy of a Nav1.7 Selective Sodium Channel Blocker in Patients With Trigeminal Neuralgia: A Double-blind, Placebo-controlled, Randomised Withdrawal Phase 2a Trial,” The Lancet Neurology 16 (2017): 291–300.

[350] H. Okuda, S. Inoue, Y. Oyamada, A. Koizumi, and S. Youssefian, “Reduced Pain Sensitivity of Episodic Pain Syndrome Model Mice Carrying a Nav1.9 Mutation by ANP-230, a Novel Sodium Channel Blocker,” Heliyon 9 (2023): e15423.

[351] H. J. Hijma, E. M. J. van Brummelen, P. S. Siebenga, and G. J. Groeneveld, “A Phase I, Randomized, Double-blind, Placebo-controlled, Single- and Multiple Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of VX-128, a Highly Selective Na(v) 1.8 Inhibitor, in Healthy Adults,” Clinical and Translational Science 15 (2022): 981–993.

[352] B. S. Safina, S. J. McKerrall, S. Sun, et al., “Discovery of Acyl-sulfonamide Na(v)1.7 Inhibitors GDC-0276 and GDC-0310,” Journal of Medicinal Chemistry 64 (2021): 2953–2966.

[353] F. J. Martinez, A. S. Afzal, J. A. Smith, et al., “Treatment of Persistent Cough in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Gefapixant, a P2×3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial,” Pulmonary Therapy 7 (2021): 471–486.

[354] M. Moens, J. Jansen, A. De Smedt, et al., “Acceptance and Commitment Therapy to Increase Resilience in Chronic Pain Patients: A Clinical Guideline,” Medicina (Kaunas, Lithuania) 58 (2022): 499.

[355] T. Mallick-Searle, K. Sharma, P. Toal, and A. Gutman, “Pain and Function in Chronic Musculoskeletal Pain-Treating the Whole Person,” Journal of Multidisciplinary Healthcare 14 (2021): 335–347.

[356] H. Oakes, M. De Vivo, D. Stephensen, and H. Mills, “Learning to Swim With Back Pain: A Qualitative Study of Swimmers With Chronic Low Back Pain,” International Journal of Qualitative Studies on Health 20 (2025): 2474357.

[357] K. A. Sluka, L. Frey-Law, and M. Hoeger Bement, “Exercise-induced pain and analgesia? Underlying Mechanisms and Clinical Translation,” Pain 159, no. Suppl 1 (2018): S91–S97.

[358] M. I. Johnson, C. A. Paley, G. Jones, M. R. Mulvey, and P. G. Wittkopf, “Efficacy and Safety of Transcutaneous Electrical Nerve Stimulation (TENS) for Acute and Chronic Pain in Adults: A Systematic Review and Meta-analysis of 381 Studies (the meta-TENS study),” Bmj Open 12 (2022): e051073.

[359] C. A. Paley, P. G. Wittkopf, G. Jones, and M. I. Johnson, “Does TENS Reduce the Intensity of Acute and Chronic Pain? A Comprehensive Appraisal of the Characteristics and Outcomes of 169 Reviews and 49 Meta-Analyses,” Medicina (Kaunas, Lithuania) 57 (2021): 1060.

[360] Z. Yu, R. Wang, W. Wei, et al., “A Coordinate-based Meta-analysis of Acupuncture for Chronic Pain: Evidence From fMRI Studies,” Frontiers in Neuroscience-Switz 16 (2022): 1049887.

[361] Z. Feng, S. Cui, H. Yang, et al., “Acupuncture for Neuropathic Pain: A Meta-analysis of Randomized Control Trials,” Frontiers in Neurology 13 (2023): 1076993.

[362] Z. Zambelli, E. J. Halstead, R. Iles, A. R. Fidalgo, and D. Dimitriou, “The 2021 NICE Guidelines for Assessment and Management of Chronic Pain: A Cross-sectional Study Mapping Against a Sample of 1,000* in the Community,” British Journal of Pain 16 (2022): 439–449.

[363] R. Trybulski, A. Kużdżał, A. Stanula, et al., “Acute effects of cold, heat and contrast pressure therapy on forearm muscles regeneration in combat sports athletes: A randomized clinical trial,” Scientific Reports-UK 14 (2024): 22410.

[364] S. Mak, J. Allen, M. Begashaw, et al., “Use of Massage Therapy for Pain, 2018–2023: A Systematic Review,” JAMA Network Open 7 (2024): e2422259.

[365] J. Yang, W. L. A. Lo, F. Zheng, X. Cheng, Q. Yu, and C. Wang, “Evaluation of Cognitive Behavioral Therapy on Improving Pain, Fear Avoidance, and Self-Efficacy in Patients With Chronic Low Back Pain: A Systematic Review and Meta-Analysis,” Pain Research & Management 2022 (2022): 4276175.

[366] M. Gandy, S. T. Y. Pang, A. J. Scott, et al., “Internet-delivered Cognitive and Behavioural Based Interventions for Adults With Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials,” Pain 163 (2022): e1041–e1053.

[367] Q. Zhang, H. Xu, Y. Wang, J. Jiang, Q. Xue, and Z. Qiu, “Efficacy of Cognitive Behavioral Therapy for Reducing Pain Susceptibility and Increasing Social Engagement in Patients With Chronic Low Back Pain: A Systematic Review and Meta-analysis,” Medicine 102 (2023): e35269.

[368] J. W. Burns, B. P. Van Dyke, A. K. Newman, C. A. Morais, and B. E. Thorn, “Cognitive Behavioral Therapy (CBT) and Pain Education for People With Chronic Pain: Tests of Treatment Mechanisms,” Journal of Consulting and Clinical Psychology 88 (2020): 1008–1018.

[369] L. Ye, Y. Li, Q. Deng, X. Zhao, L. Zhong, and L. Yang, “Acceptance and Commitment Therapy for Patients With Chronic Pain: A Systematic Review and Meta-analysis on Psychological Outcomes and Quality of Life,” PLoS ONE 19 (2024): e0301226.

[370] T. Ma, A. S. Yuen, and Z. Yang, “The Efficacy of Acceptance and Commitment Therapy for Chronic Pain: A Systematic Review and Meta-analysis,” The Clinical Journal of Pain 39 (2023): 147–157.

[371] C. Cojocaru, C. O. Popa, A. Schenk, et al., “A Single-Session Process-Based Cognitive-Behavioral Intervention Combined With Multimodal Rehabilitation Treatment for Chronic Pain Associated With Emotional Disorders,” Behavioral Sciences-Basel 14 (2024): 327.

[372] A. Lazaridou, M. Paschali, E. S. Vilsmark, et al., “Biofeedback EMG Alternative Therapy for Chronic Low Back Pain (the BEAT-pain study),” Digital Health 9 (2023): 20552076231154386.

[373] E. Lee and S. Lee, “Impact of Cervical Sensory Feedback for Forward Head Posture on Headache Severity and Physiological Factors in Patients With Tension-type Headache: A Randomized, Single-Blind, Controlled Trial,” Medical Science Monitor 25 (2019): 9572–9584.

[374] C. Marske, S. Shah, A. Chavira, et al., “Mindfulness-Based Stress Reduction in the Management of Chronic Pain and Its Comorbid Depression,” The Journal of the American Osteopathic Association 120 (2020): 575–581.

[375] M. Ploesser and D. Martin, “Mechanism of Action of Mindfulness-Based Interventions for Pain Relief-A Systematic Review,” Journal of Integrative and Complementary Medicine 30 (2024): 1162–1178.

[376] R. Gao, W. Wu, J. Xiang, et al., “Hepatocyte Culture in Autologous Decellularized Spleen Matrix,” Organogenesis 11 (2015): 16–29.

[377] L. Carlin, Q. J. Zhao, D. Bhatia, P. Taenzer, J. Flannery, and A. D. Furlan, “Keep Trying': A Qualitative Investigation Into What Patients With Chronic Pain Gain From Project ECHO,” Sage Open Medicine 12 (2024): 20503121241254941.

[378] F. Maas Genannt Bermpohl, L. Hülsmann, and A. Martin, “Efficacy of Mindfulness- and Acceptance-based Cognitive-behavioral Therapies for Bodily Distress in Adults: A Meta-analysis,” Frontiers in Psychiatry 14 (2023): 1160908.

[379] V. Varshney, J. Osborn, R. Chaturvedi, V. Shah, and K. Chakravarthy, “Advances in the Interventional Management of Neuropathic Pain,” Annals of Translational Medicine 9 (2021): 187.

[380] R. N. Harden, C. S. McCabe, A. Goebel, et al., “Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition,” Pain Medicine (Malden, Mass) 23 (2022): S1–53.

[381] M. Admiraal, P. Marhofer, P. M. Hopkins, and M. W. Hollmann, “Peripheral Regional Anaesthesia and Outcomes: A Narrative Review of the Literature From 2013 to 2023,” British Journal of Anaesthesia 132 (2024): 1082–1096.

[382] S. Zhang, L. Chen, S. R. Ladez, A. Seferge, J. Liu, and B. Feng, “Blocking Aδ- and C-fiber Neural Transmission by Sub-kilohertz Peripheral Nerve Stimulation,” Frontiers in Neuroscience-Switz 18 (2024): 1404903.

[383] A. Conger, J. Gililland, L. Anderson, C. E. Pelt, C. Peters, and Z. L. McCormick, “Genicular Nerve Radiofrequency Ablation for the Treatment of Painful Knee Osteoarthritis: Current Evidence and Future Directions,” Pain Medicine (Malden, Mass) 22 (2021): S20–S23.

[384] Y. S. Chen, B. Liu, F. Gu, and L. Sima, “Radiofrequency Denervation on Lumbar Facet Joint Pain in the Elderly: A Randomized Controlled Prospective Trial,” Pain Physician 25 (2022): 569–576.

[385] J. L. Swanson, “Genicular Nerve Radiofrequency Ablation: An Option for Knee Osteoarthritis Pain,” Jaapa-Journal of the American Academy of Physician 36 (2023): 32–36.

[386] H. Kwon, C. Kim, D. Kim, J. Shin, D. Choi, and S. Choi, “Effectiveness of the Cooled Radiofrequency Ablation of Genicular Nerves in Patients with Chronic Knee Pain Due to Osteoarthritis: A Double-Blind, Randomized, Controlled Study,” Medicina (Kaunas, Lithuania) 60 (2024): 857.

[387] Z. L. McCormick, H. Choi, R. Reddy, et al., “Randomized Prospective Trial of Cooled versus Traditional Radiofrequency Ablation of the Medial Branch Nerves for the Treatment of Lumbar Facet Joint Pain,” Regional Anesthesia & Pain Medicine 44 (2019): 389–397.

[388] E. H. El-Hakeim, A. Elawamy, E. Z. Kamel, et al., “Fluoroscopic Guided Radiofrequency of Genicular Nerves for Pain Alleviation in Chronic Knee Osteoarthritis: A Single-Blind Randomized Controlled Trial,” Pain Physician 21 (2018): 169–177.

[389] L. Huo, D. Yu, T. Feng, et al., “Comparison of Clinical Efficacy Between Percutaneous Endoscopic Transforaminal Discectomy and Coblation Nucleoplasty in the Treatment of Inclusive Lumbar Disc Herniation,” Zhongguo Gu Shang = China Journal of Orthopaedics and Traumatology 36 (2023): 17–24.

[390] M. Chęciński, K. Chęcińska, N. Turosz, et al., “Autologous Stem Cells Transplants in the Treatment of Temporomandibular Joints Disorders: A Systematic Review and Meta-Analysis of Clinical Trials,” Cells-Basel 11 (2022): 2709.

[391] J. Karri, M. Joshi, G. Polson, et al., “Spinal Cord Stimulation for Chronic Pain Syndromes: A Review of Considerations in Practice Management,” Pain Physician 23 (2020): 599–616.

[392] E. Isagulyan, K. Slavin, N. Konovalov, et al., “Spinal Cord Stimulation in Chronic Pain: Technical Advances,” Korean Journal of Pain 33 (2020): 99–107.

[393] J. M. Eckermann, J. G. Pilitsis, C. Vannaboutathong, B. J. Wagner, R. Province-Azalde, and M. A. Bendel, “Systematic Literature Review of Spinal Cord Stimulation in Patients with Chronic Back Pain without Prior Spine Surgery,” Neuromodulation: Journal of the International Neuromodulation Society 25 (2022): 648–656.

[394] G. Baranidharan, D. Edgar, B. Bretherton, et al., “Efficacy and Safety of 10 kHz Spinal Cord Stimulation for the Treatment of Chronic Pain: A Systematic Review and Narrative Synthesis of Real-World Retrospective Studies,” Biomedicines 9 (2021): 180.

[395] A. Conger, B. P. Sperry, C. W. Cheney, et al., “The Effectiveness of Spinal Cord Stimulation for the Treatment of Axial Low Back Pain: A Systematic Review With Narrative Synthesis,” Pain Medicine (Malden, Mass) 21 (2020): 2699–2712.

[396] L. Kapural, N. A. Mekhail, S. Costandi, et al., “Durable Multimodal and Holistic Response for Physiologic Closed-loop Spinal Cord Stimulation Supported by Objective Evidence From the EVOKE Double-blind Randomized Controlled Trial,” Regional Anesthesia & Pain Medicine 49 (2024): 233–240.

[397] L. C. Ong Sio, B. Hom, S. Garg, and A. Abd-Elsayed, “Mechanism of Action of Peripheral Nerve Stimulation for Chronic Pain: A Narrative Review,” International Journal of Molecular Sciences 24 (2023): 4540.

[398] J. Mossner, N. B. Saleh, M. N. Shahin, J. M. Rosenow, and J. S. Raskin, “Occipital Nerve Stimulation in Pediatric Patients With Refractory Occipital Neuralgia,” Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery 40 (2024): 2465–2470.

[399] D. X. Liu, D. V. Lam, Y. Gao, et al., “Characterization of a Temporary Peripheral Nerve Stimulation Electrode Utilizing a Bioabsorbable Suture Substrate,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference 2022 (2022): 5094–5098.

[400] C. T. Vangeison, D. J. Bintrim, J. Helms, A. K. Saha, A. N. Samant, and M. Chung, “The Role of Peripheral Nerve Stimulation in Refractory Non-operative Chronic Knee Osteoarthritis,” Pain Management 13 (2023): 213–218.

[401] N. Strand, R. S. D'Souza, J. M. Hagedorn, et al., “Evidence-Based Clinical Guidelines From the American Society of Pain and Neuroscience for the Use of Implantable Peripheral Nerve Stimulation in the Treatment of Chronic Pain,” Journal of Pain Research 15 (2022): 2483–2504.

[402] M. Nüssel, Y. Zhao, C. Knorr, et al., “Deep Brain Stimulation, Stereotactic Radiosurgery and High-Intensity Focused Ultrasound Targeting the Limbic Pain Matrix: A Comprehensive Review,” Pain and Therapy 11 (2022): 459–476.

[403] M. Abdallat, A. Saryyeva, C. Blahak, et al., “Centromedian-Parafascicular and Somatosensory Thalamic Deep Brain Stimulation for Treatment of Chronic Neuropathic Pain: A Contemporary Series of 40 Patients,” Biomedicines 9 (2021): 731.

[404] P. Shirvalkar, K. K. Sellers, A. Schmitgen, et al., “A Deep Brain Stimulation Trial Period for Treating Chronic Pain,” Journal of Clinical Medicine 9 (2020): 3155.

[405] K. Yu, X. Niu, and B. He, “Neuromodulation Management of Chronic Neuropathic Pain in the Central Nervous System,” Advanced Functional Materials 30 (2020): 1908999.

[406] H. Xiong, J. Zheng, and X. Wang, “Non-invasive Brain Stimulation for Chronic Pain: State of the Art and Future Directions,” Frontiers in Molecular Neuroscience 15 (2022): 888716.

[407] J. Yoon, H. Son, J. Lee, and G. Byeon, “Multimodal Management Strategies for Chronic Pain After Spinal Surgery: A Comprehensive Review,” Anesthesia and Pain Medicine 19 (2024): 12–23.

[408] L. M. McCracken, “Personalized Pain Management: Is It Time for Process-based Therapy for Particular People With Chronic Pain?,” European Journal of Pain (London, England) 27 (2023): 1044–1055.

[409] L. Goudman, J. Jansen, M. Billot, et al., “Virtual Reality Applications in Chronic Pain Management: Systematic Review and Meta-analysis,” JMIR Serious Games 10 (2022): e34402.

[410] G. Berardi, L. Frey-Law, K. A. Sluka, et al., “Multi-Site Observational Study to Assess Biomarkers for Susceptibility or Resilience to Chronic Pain: The Acute to Chronic Pain Signatures (A2CPS) Study Protocol,” Frontiers in Medicine-Lausanne 9 (2022): 849214.

[411] M. T. Smith, “Nonopioid Analgesics Discovery and the Valley of Death: EMA401 From Concept to Clinical Trial,” Pain 163 (2022): S15–28.

[412] A. S. Yekkirala, D. P. Roberson, B. P. Bean, and C. J. Woolf, “Breaking Barriers to Novel Analgesic Drug Development,” Nature Reviews Drug Discovery 16 (2017): 545–564.

[413] J. S. Gewandter, R. H. Dworkin, D. C. Turk, et al., “Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations,” The Journal of Pain 21 (2020): 931–942.

[414] J. S. Mogil, “Animal Models of Pain: Progress and Challenges,” Nature Reviews Neuroscience 10 (2009): 283–294.

[415] Y. I. Asiri, S. S. Moni, M. Ramar, and K. Chidambaram, “Advancing Pain Understanding and Drug Discovery: Insights From Preclinical Models and Recent Research Findings,” Pharmaceuticals-Base 17 (2024): 1439.

[416] A. V. Apkarian, M. C. Bushnell, R. Treede, and J. Zubieta, “Human Brain Mechanisms of Pain Perception and Regulation in Health and Disease,” European Journal of Pain (London, England) 9 (2005): 463–484.

[417] A. George, M. Marziniak, M. Schäfers, K. V. Toyka, and C. Sommer, “Thalidomide Treatment in Chronic Constrictive Neuropathy Decreases Endoneurial Tumor Necrosis Factor-alpha, Increases Interleukin-10 and Has Long-term Effects on Spinal Cord Dorsal Horn Met-enkephalin,” Pain 88 (2000): 267–275.

[418] L. F. Da Silva, J. M. Desantana, and K. A. Sluka, “Activation of NMDA Receptors in the Brainstem, Rostral Ventromedial Medulla, and Nucleus Reticularis Gigantocellularis Mediates Mechanical Hyperalgesia Produced by Repeated Intramuscular Injections of Acidic Saline in Rats,” The Journal of Pain 11 (2010): 378–387.

[419] Y. Li, M. J. Dorsi, R. A. Meyer, and A. J. Belzberg, “Mechanical Hyperalgesia After an L5 Spinal Nerve Lesion in the Rat Is Not Dependent on Input From Injured Nerve Fibers,” Pain 85 (2000): 493–502.

[420] J. M. Chung, H. K. Kim, and K. Chung, “Segmental Spinal Nerve Ligation Model of Neuropathic Pain,” Methods in Molecular Medicine 99 (2004): 35–45.

[421] Y. Gao and R. Ji, “Chemokines, Neuronal-glial Interactions, and central Processing of Neuropathic Pain,” Pharmacology and Therapeutics 126 (2010): 56–68.

[422] L. R. Watkins, E. D. Milligan, and S. F. Maier, “Glial Activation: A Driving Force for Pathological Pain,” Trends in Neuroscience (Tins) 24 (2001): 450–455.

[423] S. J. Medhurst, K. Walker, M. Bowes, et al., “A Rat Model of Bone Cancer Pain,” Pain 96 (2002): 129–140.

[424] L. Menéndez, A. Lastra, A. Meana, A. Hidalgo, and A. Baamonde, “Analgesic Effects of Loperamide in Bone Cancer Pain in Mice,” Pharmacology Biochemistry and Behavior 81 (2005): 114–121.

[425] Y. T. Ortiz, L. G. Shamir, L. R. McMahon, and J. L. Wilkerson, “Characterization of Commercially Available Murine Fibrosarcoma NCTC-2472 Cells both in Vitro and as a Model of Bone Cancer Pain in Vivo,” PLoS ONE 19 (2024): e0309398.

[426] D. M. Abdelaziz, L. S. Stone, and S. V. Komarova, “Osteolysis and Pain Due to Experimental Bone Metastases Are Improved by Treatment With Rapamycin,” Breast Cancer Research and Treatment 143 (2014): 227–237.

[427] E. C. Urch, T. Donovan-Rodriguez, and H. A. Dickenson, “Alterations in Dorsal Horn Neurones in a Rat Model of Cancer-induced Bone Pain,” Pain 106 (2003): 347–356.

[428] T. Okui, M. Hiasa, S. Ryumon, et al., “The HMGB1/RAGE Axis Induces Bone Pain Associated With Colonization of 4T1 Mouse Breast Cancer in Bone,” Journal of Bone Oncology 26 (2020): 100330.

[429] S. H. J. Sliepen, M. Diaz-Delcastillo, J. Korioth, et al., “Cancer-induced Bone Pain Impairs Burrowing Behaviour in Mouse and Rat,” In Vivo (Athens, Greece) 33 (2019): 1125–1132.

[430] Y. Yang, H. Li, T. Li, et al., “Delayed Activation of Spinal Microglia Contributes to the Maintenance of Bone Cancer Pain in Female Wistar Rats via P2×7 Receptor and IL-18,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 35 (2015): 7950–7963.

[431] M. Diaz-delCastillo, R. B. Hansen, C. K. Appel, et al., “Modulation of Rat Cancer-Induced Bone Pain Is Independent of Spinal Microglia Activity,” Cancers 12 (2020): 2740.

[432] K. Naik, M. N. Janal, J. Chen, et al., “The Histopathology of Oral Cancer Pain in a Mouse Model and a Human Cohort,” Journal of Dental Research 100 (2021): 194–200.

[433] C. Pacharinsak and A. Beitz, “Animal Models of Cancer Pain,” Comparative Medicine 58 (2008): 220–233.

[434] M. White, “Mediators of Inflammation and the Inflammatory Process,” Journal of Allergy and Clinical Immunology 103 (1999): S378–S381.

[435] C. A. Winter, E. A. Risley, and G. W. Nuss, “Carrageenin-induced Edema in Hind Paw of the Rat as an Assay for Antiiflammatory Drugs,” Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY) 111 (1962): 544–547.

[436] J. Yang, Y. Xie, R. Smith, S. Ratté, and S. A. Prescott, “Discordance Between Preclinical and Clinical Testing of Na V 1.7-selective Inhibitors for Pain,” Pain 166 (2025): 481–501.

[437] R. S. Y. Ma, K. Kayani, D. Whyte-Oshodi, et al., “Voltage Gated Sodium Channels as Therapeutic Targets for Chronic Pain,” Journal of Pain Research 12 (2019): 2709–2722.

[438] S. D. Dib-Hajj, A. M. Binshtok, T. R. Cummins, M. F. Jarvis, T. Samad, and K. Zimmermann, “Voltage-gated Sodium Channels in Pain States: Role in Pathophysiology and Targets for Treatment,” Brain Research Reviews 60 (2009): 65–83.

[439] S. D. Dib-Hajj, T. R. Cummins, J. A. Black, and S. G. Waxman, “Sodium Channels in Normal and Pathological Pain,” Annual Review of Neuroscience 33 (2010): 325–347.

[440] F. C. Cardoso and R. J. Lewis, “Sodium Channels and Pain: From Toxins to Therapies,” British Journal of Pharmacology 175 (2018): 2138–2157.

[441] J. S. Mogil and M. L. Chanda, “The Case for the Inclusion of Female Subjects in Basic Science Studies of Pain,” Pain 117 (2005): 1–5.

[442] J. Jones, D. J. Correll, S. M. Lechner, et al., “Selective Inhibition of Na(V)1.8 With VX-548 for Acute Pain,” The New England Journal of Medicine 389 (2023): 393–405.

[443] K. Kingwell, “Na(V)1.8 Inhibitor Poised to Provide Opioid-free Pain Relief,” Nature Reviews Drug Discovery 24 (2025): 3–5.

[444] C. J. Laedermann, H. Abriel, and I. Decosterd, “Post-translational Modifications of Voltage-gated Sodium Channels in Chronic Pain Syndromes,” Frontiers in Pharmacology 6 (2015): 263.

[445] P. Vanelderen, T. Rouwette, T. Kozicz, et al., “Effects of Chronic Administration of Amitriptyline, Gabapentin and Minocycline on Spinal Brain-derived Neurotrophic Factor Expression and Neuropathic Pain Behavior in a Rat Chronic Constriction Injury Model,” Regional Anesthesia & Pain Medicine 38 (2013): 124–130.

[446] P. Vanelderen, J. Van Zundert, T. Kozicz, et al., “Effect of Minocycline on Lumbar Radicular Neuropathic Pain: A Randomized, Placebo-controlled, Double-blind Clinical Trial With Amitriptyline as a Comparator,” Anesthesiology 122 (2015): 399–406.

[447] V. Martinez, B. Szekely, J. Lemarié, et al., “The Efficacy of a Glial Inhibitor, minocycline, for Preventing Persistent Pain After Lumbar Discectomy: A Randomized, Double-blind, Controlled Study,” Pain 154 (2013): 1197–1203.

[448] M. Zarei, M. Sabetkasaei, and T. Moini-Zanjani, “Paradoxical Effect of Minocycline on Established Neuropathic Pain in Rat,” Excli Journal 16 (2017): 229–235.

[449] T. Y. Chin, S. S. Kiat, H. G. Faizul, W. Wu, and J. M. Abdullah, “The Effects of Minocycline on Spinal Root Avulsion Injury in Rat Model,” Malaysian Journal of Medical Sciences 24 (2017): 31–39.

[450] D. A. Shin, T. U. Kim, and M. C. Chang, “Minocycline for Controlling Neuropathic Pain: A Systematic Narrative Review of Studies in Humans,” Journal of Pain Research 14 (2021): 139–145.

[451] Y. Chu, Y. Zhang, Y. Zhang, and Z. Zhao, “Involvement of Microglial P2×7 Receptors and Downstream Signaling Pathways in Long-term Potentiation of Spinal Nociceptive Responses,” Brain, Behavior, and Immunity 24 (2010): 1176–1189.

[452] K. Recourt, P. de Boer, P. van der Ark, et al., “Characterization of the central Nervous System Penetrant and Selective Purine P2×7 Receptor Antagonist JNJ-54175446 in Patients With Major Depressive Disorder,” Translational Psychiatry 13 (2023): 266.

[453] A. Mullard, “GSK Buys Purine Receptor Antagonist for $2 Billion,” Nature Reviews Drug Discovery 22 (2023): 435.

[454] R. Yang, Z. Li, Y. Zou, et al., “Gallic Acid Alleviates Neuropathic Pain Behaviors in Rats by Inhibiting P2×7 Receptor-Mediated NF-κB/STAT3 Signaling Pathway,” Frontiers in Pharmacology 12 (2021): 680139.

[455] A. K. Clark and M. Malcangio, “Fractalkine/CX3CR1 Signaling During Neuropathic Pain,” Frontiers in Cellular Neuroscience 8 (2014): 121.

[456] Z. Zhuang, Y. Kawasaki, P. Tan, Y. Wen, J. Huang, and R. Ji, “Role of the CX3CR1/p38 MAPK Pathway in Spinal Microglia for the Development of Neuropathic Pain Following Nerve Injury-induced Cleavage of Fractalkine,” Brain, Behavior, and Immunity 21 (2007): 642–651.

[457] R. Silva and M. Malcangio, “Fractalkine/CX(3)CR(1) Pathway in Neuropathic Pain: An Update,” Frontiers in Pain Research (Lausanne, Switzerland) 2 (2021): 684684.

[458] N. Mahroum and Y. Shoenfeld, “Autoimmune Autonomic Dysfunction Syndromes: Potential Involvement and Pathophysiology Related to Complex Regional Pain Syndrome, Fibromyalgia, Chronic Fatigue Syndrome, Silicone Breast Implant-Related Symptoms and Post-COVID Syndrome,” Pathophysiology: The Official Journal of the International Society for Pathophysiology 29 (2022): 414–425.

[459] S. P. Cohen, N. Bogduk, A. Dragovich, et al., “Randomized, Double-blind, Placebo-controlled, Dose-response, and Preclinical Safety Study of Transforaminal Epidural Etanercept for the Treatment of Sciatica,” Anesthesiology 110 (2009): 1116–1126.

[460] J. G. Guedon, S. Wu, X. Zheng, et al., “Current Gene Therapy Using Viral Vectors for Chronic Pain,” Molecular Pain 11 (2015): 27.

[461] F. E. M. Froeling, C. Feig, C. Chelala, et al., “Retinoic Acid-induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt-β-catenin Signaling to Slow Tumor Progression,” Gastroenterology 141 (2011): 1486.

[462] S. Hao, M. Mata, W. Goins, J. C. Glorioso, and D. J. Fink, “Transgene-mediated Enkephalin Release Enhances the Effect of Morphine and Evades Tolerance to Produce a Sustained Antiallodynic Effect in Neuropathic Pain,” Pain 102 (2003): 135–142.

[463] D. Wolfe, M. Mata, and D. J. Fink, “A human Trial of HSV-mediated Gene Transfer for the Treatment of Chronic Pain,” Gene Therapy 16 (2009): 455–460.

[464] J. Braz, C. Beaufour, A. Coutaux, et al., “Therapeutic Efficacy in Experimental Polyarthritis of Viral-driven Enkephalin Overproduction in Sensory Neurons,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 21 (2001): 7881–7888.

[465] A. Meunier, A. Latrémolière, A. Mauborgne, et al., “Attenuation of Pain-related Behavior in a Rat Model of Trigeminal Neuropathic Pain by Viral-driven Enkephalin Overproduction in Trigeminal Ganglion Neurons,” Molecular Therapy 11 (2005): 608–616.

[466] J. R. Goss, C. F. Harley, M. Mata, et al., “Herpes Vector-mediated Expression of Proenkephalin Reduces Bone Cancer Pain,” Annals of Neurology 52 (2002): 662–665.

[467] D. J. Fink, J. Wechuck, M. Mata, et al., “Gene Therapy for Pain: Results of a Phase I Clinical Trial,” Annals of Neurology 70 (2011): 207–212.

[468] M. Chattopadhyay, M. Mata, and D. J. Fink, “Vector-mediated Release of GABA Attenuates Pain-related Behaviors and Reduces Na(V)1.7 in DRG Neurons,” European Journal of Pain (London, England) 15 (2011): 913–920.

[469] S. Hao, M. Mata, J. C. Glorioso, and D. J. Fink, “HSV-mediated Expression of Interleukin-4 in Dorsal Root Ganglion Neurons Reduces Neuropathic Pain,” Molecular Pain 2 (2006): 6.

[470] Z. Zhou, X. Peng, S. Hao, D. J. Fink, and M. Mata, “HSV-mediated Transfer of Interleukin-10 Reduces Inflammatory Pain Through Modulation of Membrane Tumor Necrosis Factor Alpha in Spinal Cord Microglia,” Gene Therapy 15 (2008): 183–190.

[471] A. M. Moreno, F. Alemán, G. F. Catroli, et al., “Long-lasting Analgesia via Targeted in Situ Repression of Na(V)1.7 in Mice,” Science Translational Medicine 13 (2021): eaay9056.

[472] A. Gonzalez Alvarez, S. Ananth, L. Dovgalski, and P. L. Evans, “Custom Three-dimensional Printed Orbital Plate Composed of Two Joined Parts With Variable Thickness for a Large Orbital Floor Reconstruction After Post-traumatic Zygomatic Fixation,” The British Journal of Oral & Maxillofacial Surgery 58 (2020): e341–e342.

[473] B. Sadeghirad, Y. Rehman, A. Khosravirad, et al., “Mesenchymal Stem Cells for Chronic Knee Pain Secondary to Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Trials,” Osteoarthritis and Cartilage 32 (2024): 1207–1219.

[474] F. Crichton and K. J. Petrie, “Health Complaints and Wind Turbines: The Efficacy of Explaining the Nocebo Response to Reduce Symptom Reporting,” Environmental Research 140 (2015): 449–455.

[475] L. Colloca, A. Han, R. Massalee, et al., “Telehealth Virtual Reality Intervention Reduces Chronic Pain in a Randomized Crossover Study,” Npj Digital Medicine 8 (2025): 192.

[476] B. D. Darnall, P. Krishnamurthy, J. Tsuei, and J. D. Minor, “Self-Administered Skills-Based Virtual Reality Intervention for Chronic Pain: Randomized Controlled Pilot Study,” JMIR Formative Research 4 (2020): e17293.

[477] T. Maddox, L. Oldstone, C. Y. Sparks, et al., “In-Home Virtual Reality Program for Chronic Lower Back Pain: A Randomized Sham-Controlled Effectiveness Trial in a Clinically Severe and Diverse Sample,” Mayo Clinic Proceedings Digital Health 1 (2023): 563–573.

[478] J. D. Piette, S. Newman, S. L. Krein, et al., “Patient-Centered Pain Care Using Artificial Intelligence and Mobile Health Tools: A Randomized Comparative Effectiveness Trial,” JAMA Internal Medicine 182 (2022): 975–983.

[479] A. Ferrero, G. Lambert, F. Caretto, M. Trucco, L. Piano, and A. Chiarotto, “Effectiveness of Mobile Apps in the Rehabilitation of Patients With Low Back Pain. A systematic review with meta-analysis of randomized controlled trials,” Archives of Physical Medicine and Rehabilitation (2025), (forthcoming), https://doi.org/10.1016/j.apmr.2025.08.023.

[480] S. Meheli, C. Sinha, and M. Kadaba, “Understanding People with Chronic Pain Who Use a Cognitive Behavioral Therapy-Based Artificial Intelligence Mental Health App (Wysa): Mixed Methods Retrospective Observational Study,” JMIR Human Factors 9 (2022): e35671.

[481] C. Sinha, A. L. Cheng, and M. Kadaba, “Adherence and Engagement with a Cognitive Behavioral Therapy-Based Conversational Agent (Wysa for Chronic Pain) among Adults with Chronic Pain: Survival Analysis,” JMIR Formative Research 6 (2022): e37302.

[482] P. G. Conaghan, N. Katz, A. R. Bihlet, et al., “Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee: A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial,” Lancet (London, England) 407 (2026): 1237–1248.

[483] X. Shang, Z. Wang, and H. Tao, “Mechanism and Therapeutic Effectiveness of Nerve Growth Factor in Osteoarthritis Pain,” Therapeutics and Clinical Risk Management 13 (2017): 951–956.

[484] J. Nagai, H. Uchida, Y. Matsushita, et al., “Autotaxin and Lysophosphatidic acid1 Receptor-mediated Demyelination of Dorsal Root Fibers by Sciatic Nerve Injury and Intrathecal Lysophosphatidylcholine,” Molecular Pain 6 (2010): 78.

[485] H. Ueda, H. Neyama, J. Nagai, Y. Matsushita, T. Tsukahara, and R. Tsukahara, “Involvement of Lysophosphatidic Acid-induced Astrocyte Activation Underlying the Maintenance of Partial Sciatic Nerve Injury-induced Neuropathic Pain,” Pain 159 (2018): 2170–2178.

[486] R. Ciccocioppo, J. Gudin, C. E. Argoff, et al., “The Therapeutic Potential of Dual NMR (NOP/MOP) Agonism in Pain Management,” Pain and Therapy 15 (2026): 71–95.

[487] F. Yang, Q. Xu, B. Shu, et al., “Activation of Cannabinoid CB1 Receptor Contributes to Suppression of Spinal Nociceptive Transmission and Inhibition of Mechanical Hypersensitivity by Aβ-fiber Stimulation,” Pain 157 (2016): 2582–2593.

[488] K. Xu, Y. Wu, Z. Tian, Y. Xu, C. Wu, and Z. Wang, “Microglial Cannabinoid CB(2) Receptors in Pain Modulation,” International Journal of Molecular Sciences 24 (2023): 2348.

[489] M. Ashina, R. Phul, M. Khodaie, E. Löf, and I. Florea, “A Monoclonal Antibody to PACAP for Migraine Prevention,” The New England Journal of Medicine 391 (2024): 800–809.

[490] A. U. Syed, M. Koide, K. M. Braas, V. May, and G. C. Wellman, “Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Potently Dilates Middle Meningeal Arteries: Implications for Migraine,” Journal of Molecular Neuroscience: MN 48 (2012): 574–583.

[491] A. Markovics, V. Kormos, B. Gaszner, et al., “Pituitary Adenylate Cyclase-activating Polypeptide Plays a Key Role in Nitroglycerol-induced Trigeminovascular Activation in Mice,” Neurobiology of Disease 45 (2012): 633–644.

[492] L. Zhang, Y. Zhou, L. Yang, Y. Wang, and Z. Xiao, “PACAP6-38 improves Nitroglycerin-induced central Sensitization by Modulating Synaptic Plasticity at the Trigeminal Nucleus Caudalis in a Male Rat Model of Chronic Migraine,” The Journal of Headache and Pain 24 (2023): 66.

[493] C. C. Lins, A. S. Fonseca, P. N. Martins, et al., “Investigation of Predictors of Pain Relief With High-frequency Repetitive Motor Cortex Transcranial Magnetic Stimulation Among People With Fibromyalgia,” Neurophysiologie Clinique = Clinical Neurophysiology 55 (2025): 103109.

[494] T. Taguchi, K. Katanosaka, M. Yasui, et al., “Peripheral and Spinal Mechanisms of Nociception in a Rat Reserpine-induced Pain Model,” Pain 156 (2015): 415–427.

[495] R. S. Taylor, S. P. Lad, J. L. White, et al., “Health Care Resource Utilization and Costs in Patients With Painful Diabetic Neuropathy Treated With 10 kHz Spinal Cord Stimulation Therapy,” Journal of Managed Care & Specialty Pharmacy 29 (2023): 1021–1029.

[496] K. Due Bruun, R. Christensen, K. Amris, et al., “Naltrexone 6 mg Once Daily versus Placebo in Women With Fibromyalgia: A Randomised, Double-blind, Placebo-controlled Trial,” The Lancet Rheumatology 6 (2024): e31–e39.

[497] P. S. S. Lopes, A. C. P. Campos, E. T. Fonoff, L. R. G. Britto, and R. L. Pagano, “Motor Cortex and Pain Control: Exploring the Descending Relay Analgesic Pathways and Spinal Nociceptive Neurons in Healthy Conscious Rats,” Behavioral and Brain Functions 15 (2019): 5.

[498] B. Cai, D. Wu, H. Xie, et al., “A Direct Spino-cortical Circuit Bypassing the Thalamus Modulates Nociception,” Cell Research 33 (2023): 775–789.

[499] M. Schmelz, “Pruritus-a Long Journey From Neurophysiology to the Clinic,” Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 71 (2020): 487–492.

[500] R. B. Kargbo, “Advances in Psychoactive Alkaloid Delivery, Ergoline Analogues, and Serotonin Receptor Modulation for Enhanced Therapeutic Outcomes,” Acs Medicinal Chemistry Letters 16 (2024): 26–28.

[501] C. A. Reynolds and Z. Minic, “Chronic Pain-Associated Cardiovascular Disease: The Role of Sympathetic Nerve Activity,” International Journal of Molecular Sciences 24 (2023): 5378.

[502] N. Madrer, E. R. Bennett, S. Vaknine-Treidel, M. Hanani, and H. Soreq, “Conserved Small RNA Networks Link Inflammation to Pain Signaling in Mice and Men,” Translational Psychiatry 16, no. 1 (2025): 44.

[503] J. Zhang, T. Ju, Y. Qin, M. Hou, L. Gao, and L. Wu, “Therapeutic Targeting of P2X Receptors for Orofacial Pain,” Brain Research Bulletin 224 (2025): 111301.

[504] S. Zhang, Y. Ning, Y. Yang, et al., “Decoding Pain Chronification: Mechanisms of the Acute-to-chronic Transition,” Frontiers in Molecular Neuroscience 18 (2025): 1596367.

[505] S. J. Kang, S. Liu, J. Kim, et al., “Thalamic CGRP Neurons Define a Spinothalamic Pathway for Affective Pain,” Proceedings of the National Academy of Sciences of the United States of America 122 (2025): e2505889122.

[506] L. Li, X. Fan, and R. Crawford, “Understanding Pain Heterogeneity in Osteoarthritis Patients: A Narrative Review,” Frontiers in Medicine-Prc 19 (2025): 769–788.

[507] T. Cantarelli Rodrigues, G. Cunha Filho, A. Skaf, and A. F. Yamada, “Common Mistakes in Groin Pain Classification,” Seminars in Musculoskeletal Radiology 29 (2025): 720–732.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.